Becton, Dickinson and (BDX) 10-K 21 Nov 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2018	Oct. 31, 2018	Mar. 31, 2018
Document And Entity Information [Abstract]
Entity registrant name	BECTON DICKINSON & CO
Entity central index key	10,795
Current fiscal year end date	--09-30
Entity filer category	Large Accelerated Filer
Document type	10-K
Document period end date	Sep. 30, 2018
Document fiscal year focus	2,018
Document fiscal period focus	FY
Amendment flag	false
Entity small business	false
Entity emerging growth company	false
Entity common stock, shares outstanding (shares)		268,257,940
Entity well-known seasoned issuer	Yes
Entity voluntary filers	No
Entity current reporting status	Yes
Entity shell company	false
Entity public float			$ 56,903,426,170

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenues	$ 15,983	$ 12,093	$ 12,483
Cost of products sold	8,721	6,151	6,492
Selling and administrative expense	4,015	2,925	3,005
Research and development expense	1,006	774	828
Acquisitions and other restructurings	744	354	728
Other operating expense, net	0	410	0
Total Operating Costs and Expenses	14,487	10,615	11,053
Operating Income	1,497	1,478	1,430
Interest expense	(706)	(521)	(388)
Interest income	65	76	21
Other income (expense), net	318	(57)	11
Income Before Income Taxes	1,173	976	1,074
Income tax provision (benefit)	862	(124)	97
Net Income	311	1,100	976
Preferred stock dividends	(152)	(70)	0
Net income applicable to common shareholders	$ 159	$ 1,030	$ 976
Basic Earnings per Share
Basic Earnings per Share (USD per share)	$ 0.62	$ 4.70	$ 4.59
Diluted Earnings per Share
Diluted Earnings per Share (USD per share)	$ 0.60	$ 4.60	$ 4.49

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net Income	$ 311	$ 1,100	$ 976
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(161)	11	(50)
Defined benefit pension and postretirement plans	(26)	179	(141)
Cash flow hedges	1	17	1
Other Comprehensive (Loss) Income, Net of Tax	(186)	206	(191)
Comprehensive Income	$ 125	$ 1,306	$ 786

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Current Assets
Cash and equivalents	$ 1,140	$ 14,179
Restricted cash	96	0
Short-term investments	17	21
Trade receivables, net	2,319	1,744
Inventories	2,451	1,818
Assets held for sale	137	0
Prepaid expenses and other	1,251	871
Total Current Assets	7,411	18,633
Property, Plant and Equipment, Net	5,375	4,638
Goodwill	23,600	7,563
Developed Technology, Net	12,184	2,478
Customer Relationships, Net	3,723	2,830
Other Intangibles, Net	534	585
Other Assets	1,078	1,007
Total Assets	53,904	37,734
Current Liabilities
Short-term debt	2,601	203
Accounts payable	1,106	797
Accrued expenses	2,255	1,393
Salaries, wages and related items	910	773
Income taxes	343	176
Total Current Liabilities	7,216	3,342
Long-Term Debt	18,894	18,667
Long-Term Employee Benefit Obligations	1,056	1,168
Deferred Income Taxes and Other	5,743	1,609
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2	2
Common stock — $1 par value: authorized — 640,000,000 shares; issued — 346,687,160 shares in 2018 and 2017.	347	347
Capital in excess of par value	16,179	9,619
Retained earnings	12,596	13,111
Deferred compensation	22	19
Common stock in treasury — at cost — 78,462,971 shares in 2018 and 118,744,758 shares in 2017.	(6,243)	(8,427)
Accumulated other comprehensive loss	(1,909)	(1,723)
Total Shareholders’ Equity	20,994	12,948
Total Liabilities and Shareholders’ Equity	$ 53,904	$ 37,734

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Statement of Financial Position [Abstract]
Common stock, par value (USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	346,687,160	346,687,160
Common stock in treasury, shares (shares)	78,462,971	118,744,758

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Operating Activities
Net Income	$ 311	$ 1,100	$ 976
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	1,978	1,088	1,114
Share-based compensation	322	174	196
Deferred income taxes	(240)	(236)	(426)
Change in operating assets and liabilities:
Trade receivables, net	(170)	(93)	(128)
Inventories	246	(46)	69
Prepaid expenses and other	(46)	(366)	90
Accounts payable, income taxes and other liabilities	867	134	368
Pension obligation	(263)	84	(32)
Excess tax benefits from payments under share-based compensation plans	78	77	0
Lease contract modification-related charge	0	748	0
Gain on sale of Vyaire interest	(303)	0	0
Other, net	85	(114)	332
Net Cash Provided by Operating Activities	2,865	2,550	2,559
Investing Activities
Capital expenditures	(895)	(727)	(693)
Proceeds from (purchases of) investments, net	11	13	(1)
Acquisitions of businesses, net of cash acquired	(15,281)	(174)	0
Proceeds from divestitures, net	534	165	158
Other, net	(198)	(161)	(133)
Net Cash Used for Investing Activities	(15,829)	(883)	(669)
Financing Activities
Change in credit facility borrowings	0	(200)	(500)
Proceeds from long-term debt and term loans	5,086	11,462	0
Payments of debt and term loans	(3,996)	(3,980)	(752)
Proceeds from issuance of equity securities	0	4,827	0
Repurchase of common stock	0	(220)	0
Excess tax benefit from payments under share-based compensation plans	0	0	86
Dividends paid	(927)	(677)	(562)
Other, net	(220)	(234)	(32)
Net Cash (Used for) Provided by Financing Activities	(58)	10,977	(1,761)
Effect of exchange rate changes on cash and equivalents	(17)	(6)	(12)
Net (Decrease) Increase in Cash and Equivalents	(13,039)	12,638	117
Opening Cash and Equivalents	14,179	1,541	1,424
Closing Cash and Equivalents	1,140	14,179	1,541
Noncash Investing and Financing Items [Abstract]
Noncash consideration-fair value of shares issued	8,004	0	0
Noncash consideration-fair value of stock options and other equity awards	$ 613	$ 0	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30. Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities. Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard") which is further discussed in Note 9. Short-Term Investments Short-term investments consist of time deposits with maturities greater than three months and less than one year when purchased. Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Inventories Inventories are stated at the lower of first-in, first-out cost or market. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four to 13 years for machinery and equipment and one to 20 years for leasehold improvements. Depreciation and amortization expense was $600 million , $406 million and $452 million in fiscal years 2018 , 2017 and 2016 , respectively. Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill and in-process research and development assets which arise from acquisitions. The Company currently reviews all indefinite-lived assets, including goodwill, for impairment generally using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. Potential impairment of goodwill is generally identified by comparing the fair value of a reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2018 indicated that all identified reporting units’ fair values exceeded their respective carrying values. The review for impairment of in-process research and development assets is performed by comparing the fair value of the technology or project assets, estimated using an income approach, with their carrying value. In-process research and development assets are considered indefinite-lived assets and are reviewed at least annually for impairment until projects are completed or abandoned. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one to 40 years, using the straight-line method. Finite-lived intangible assets, including developed technology assets, are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value. Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss). Revenue Recognition Revenue from product sales is typically recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; product price is fixed or determinable; collection of the resulting receivable is reasonably assured. Certain sales arrangements contain multiple deliverables, including equipment and service deliverables, which requires the Company to determine the separate units of account. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price. Revenue allocated to certain equipment deliverables is recognized upon customer acceptance, which occurs after the transfer of title and risk of loss to the customer and the completion of installation or training services. When related services are considered inconsequential, delivery is deemed to occur upon the transfer of title and risk of loss, at which time revenue and the costs associated with services are recognized. For equipment lease revenue, transactions are evaluated and classified as either operating leases or sales-type leases. Generally, the Company's lease arrangements with customers are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period, as defined within the customer agreement. For products sold and leased with embedded software, if software is considered not essential to the non-software elements of a product but is considered more than incidental to a product as a whole, the product’s software elements must be separated from its non-software elements under the requirements relating to multiple-element arrangements and accounted for under software industry-specific revenue recognition requirements. However, if it is determined that the embedded software is more than incidental to the product as a whole but the non-software elements and software elements work together to deliver the essential functionality of the products as a whole, then the accounting for such product does not fall within the scope of software industry-specific accounting requirements. The Company’s domestic businesses sell products primarily to distributors that resell the products to end-user customers. Rebates are provided to distributors that sell to end-user customers at prices determined under a contract between the Company and the end-user customer. Provisions for rebates, as well as sales discounts and returns, are based upon estimates and are accounted for as a reduction of revenues when revenue is recognized. Shipping and Handling Costs Shipping and handling costs are included in Selling and administrative expense . Shipping expense was $479 million , $365 million and $401 million in 2018 , 2017 and 2016 , respectively. Derivative Financial Instruments All derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized. Additional disclosures regarding the Company's accounting for derivative instruments are provided in Note 13. Income Taxes The Company has historically asserted indefinite reinvestment of the earnings of certain non-U.S. subsidiaries outside the United States. New U.S. tax legislation, which is further discussed in Note 16, eliminated certain material tax effects on the repatriation of cash to the United States. Future repatriation of cash and other property held by the Company's foreign subsidiaries will generally not be subject to U.S. federal income tax. As a result, after reevaluation of the permanent reinvestment assertion, the Company is no longer permanently reinvested with respect to its historic unremitted foreign earnings as of September 30, 2018. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions, based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 16. Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.

Accounting Changes

Accounting Changes	12 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Accounting Changes	Accounting Changes New Accounting Principle Adopted In the second quarter of its fiscal year 2018, the Company prospectively adopted an accounting standard update issued by the Financial Accounting Standards Board ("FASB") relating to the stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 16. Additional disclosures regarding this accounting standard adoption are provided in Note 3. On October 1, 2016, the Company prospectively adopted amended requirements issued by the FASB relating to the timing of recognition and classification of share-based compensation award-related income tax effects. Upon adoption of the requirements in 2017, the Company has recorded tax benefits relating to share-based compensation awards within Income tax (benefit) provision on its consolidated statement of income. These tax benefits had been previously recorded within Capital in excess of par value on the Company's consolidated balance sheet. Also upon adoption of the amended guidance in 2017, the Company has classified excess tax benefits on its consolidated statement of cash flows within Net Cash Provided by Operating Activities , rather than Net Cash Provided by (Used for) Financing Activities . New Accounting Principles Not Yet Adopted In March 2017, the FASB issued an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. The Company's adoption of the new requirements on October 1, 2018 is not expected to have a material impact on its consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet. The new standard also requires expanded disclosures regarding leasing arrangements. The Company will adopt the standard on October 1, 2019 and has commenced its initial assessment of the impact on its consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard. Under this standard, revenue is recognized upon the transfer of goods or services to customers and the amount of revenue recognized reflects the consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on October 1, 2018 using the modified retrospective method. The Company assessed the impact that this new revenue recognition standard will have on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. The Company is currently finalizing the changes to its processes, systems and controls which are necessary to support recognition and disclosure under the new revenue recognition standard. The Company does not expect its adoption of the new standard to have a material impact on its consolidated financial statements.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Changes in certain components of shareholders’ equity were as follows: Common Stock Issued at Par Value Capital in Excess of Par Value Retained Earnings Deferred Compensation Treasury Stock (Millions of dollars) Shares (in thousands) Amount Balance at September 30, 2015 $ 333 $ 4,475 $ 12,314 $ 20 (121,967 ) $ (8,239 ) Net income — — 976 — — — Cash dividends: Common ($2.64 per share) — — (562 ) — — — Common stock issued for: Share-based compensation and other plans, net — 27 (1 ) 2 2,607 26 Share-based compensation — 191 — — — — Common stock held in trusts, net (a) — — — — (11 ) — Balance at September 30, 2016 $ 333 $ 4,693 $ 12,727 $ 22 (119,371 ) $ (8,212 ) Net income — — 1,100 — — — Cash dividends: Common ($2.92 per share) — — (645 ) — — — Preferred — — (70 ) — — — Common stock issued for: Public equity offerings (b) 14 4,810 — — — — Share-based compensation and other plans, net — (65 ) (1 ) (3 ) 1,908 6 Share-based compensation — 180 — — — — Common stock held in trusts, net (a) — — — — 7 — Repurchase of common stock (c) — — — — (1,289 ) (220 ) Balance at September 30, 2017 $ 347 $ 9,619 $ 13,111 $ 19 (118,745 ) $ (8,427 ) Net income — — 311 — — — Cash dividends: Common ($3.00 per share) — — (775 ) — — — Preferred — — (152 ) — — — Common stock issued for: Acquisition (see Note 9) — 6,478 — — 37,306 2,121 Share-based compensation and other plans, net — (246 ) (2 ) 3 2,982 62 Share-based compensation — 328 — — — — Common stock held in trusts, net (a) — — — — (6 ) — Effect of change in accounting principle (see Note 2 and further discussion below) — — 103 — — — Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463 ) $ (6,243 ) (a) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) In May 2017 and in connection with the Company's acquisition of Bard, which is further discussed in Note 9 , the Company completed registered public offerings of equity securities including 14.025 million shares of the Company's common stock and 2.475 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for total net proceeds of $4.8 billion . If and when declared, dividends on the mandatory convertible preferred stock are payable on a cumulative basis at an annual rate of 6.125% on the liquidation preference of $1,000 per preferred share ( $50 per depositary share). The shares of preferred stock are convertible to a minimum of 11.7 million and up to a maximum of 14.0 million shares of Company common stock at an exchange ratio that is based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of May 1, 2020. (c) Using proceeds received from the divestiture of the Respiratory Solutions business in the first quarter of fiscal year 2017, the Company repurchased shares of its common stock under an accelerated share repurchase agreement. The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Currency Translation Benefit Plans Cash Flow Hedges Balance at September 30, 2015 $ (1,738 ) $ (961 ) $ (741 ) $ (36 ) Other comprehensive loss before reclassifications, net of taxes (251 ) (50 ) (190 ) (11 ) Amounts reclassified into income, net of 60 — 48 12 Balance at September 30, 2016 $ (1,929 ) $ (1,011 ) $ (883 ) $ (35 ) Other comprehensive income before reclassifications, net of taxes 140 11 121 8 Amounts reclassified into income, net of 66 — 58 8 Balance at September 30, 2017 $ (1,723 ) $ (1,001 ) $ (703 ) $ (18 ) Other comprehensive (loss) income before reclassifications, net of taxes (142 ) (161 ) 19 — Amounts reclassified into income, net of taxes 57 — 52 5 Tax effects reclassified to retained earnings (103 ) — (99 ) (4 ) Balance at September 30, 2018 $ (1,909 ) $ (1,162 ) $ (729 ) $ (17 ) The amount of foreign currency translation recognized in other comprehensive income during the years ended September 30, 2018 and 2017 included net gains (losses) relating to net investment hedges, as further discussed in Note 13 . The amount recognized in other comprehensive income during the year ended September 30, 2017 relating to cash flow hedges represented a net gain on forward starting interest rate swaps, which is further discussed in Note 13 . During the second quarter of 2018, as permitted under U.S. GAAP guidance, the Company reclassified stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 16, to Retained earnings . The reclassified tax effects related to prior service credits and net actuarial losses relating to benefit plans, as well as to terminated cash flow hedges. The tax effects relating to these items are generally recognized as such amounts are amortized into earnings. The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2018 2017 2016 Benefit Plans Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income $ (19 ) $ (60 ) $ 79 The tax impacts for cash flow hedges recognized in other comprehensive income before reclassifications in 2017 and 2016 were immaterial to the Company's consolidated financial results. Reclassifications out of Accumulated other comprehensive income (loss) and the related tax impacts relating to benefit plans and cash flow hedges in 2018 , 2017 and 2016 were also immaterial to the Company's consolidated financial results

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2018 2017 2016 Average common shares outstanding 258,354 218,943 212,702 Dilutive share equivalents from share-based plans (a) (b) 6,267 4,645 4,834 Average common and common equivalent shares outstanding — assuming dilution 264,621 223,588 217,536 (a) For the years ended September 30, 2018 and 2017 , dilutive share equivalents associated with mandatory convertible preferred stock of 12 million and 5 million , respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3 . For the years ended September 30, 2018 , 2017 and 2016 , there were no options to purchase shares of common stock which were excluded from the diluted earnings per share calculation. (b) The adjustment to calculate diluted share equivalents from share-based plans in 2016 included excess tax benefits relating to share-based compensation awards. Upon the Company's adoption, as discussed in Note 2 , of new accounting requirements relating to share-based compensation award-related income tax effects, the adjustments in 2018 and 2017 excluded these excess tax benefits.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Rental expense for all operating leases amounted to $149 million in 2018 , $110 million in 2017 and $112 million in 2016 . Future minimum rental commitments on non-cancelable leases are as follows: 2019 — $107 million ; 2020 — $94 million ; 2021 — $76 million ; 2022 — $62 million ; 2023 — $48 million and an aggregate of $124 million thereafter. As of September 30, 2018 , the Company has certain future purchase commitments aggregating to approximately $1.046 billion , which will be expended over the next several years. Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. generally accepted accounting principles, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the investigative subpoena issued by the Department of Defense Inspector General and the Department of Health and Human Services and the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters As is further discussed in Note 9 , the Company completed its acquisition of Bard on December 29, 2017 and the following matters include Bard-related legal proceedings and claims that the Company assumed on the acquisition date (“Bard-related Product Liability Matters”). The Company believes that certain settlements and judgments, as well as some legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Hernia Product Claims As of September 30, 2018 , the Company is defending approximately 3,154 product liability claims involving Bard’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2019 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2018 , the Company is defending approximately 1,322 product liability claims involving Bard’s line of pelvic mesh devices. The majority of those claims are currently pending in a federal MDL in the United States District Court for the Southern District of West Virginia, but claims are also pending in other state and/or federal court jurisdictions, including a coordinated proceeding in New Jersey State Court. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,037 filed and unfiled claims that have been asserted or threatened against Bard but lack sufficient information to determine whether a Bard pelvic mesh device is actually at issue. The claims identified above also include products manufactured by both Bard and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of Bard. Medtronic has an obligation to defend and indemnify Bard with respect to any product defect liability relating to products its subsidiaries had manufactured. As described below, in July 2015 the Company reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects of Medtronic’s indemnification obligation. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of September 30, 2018 , the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,021 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated in 2018 and throughout 2019 in state courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ( $33 million compensatory; $35 million punitive). The Company is in the process of challenging that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months. In July 2015, as part of the agreement with Medtronic noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by Bard under supply agreements with Medtronic, and Bard has paid Medtronic $121 million towards these potential settlements. In June 2017, Bard amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. Bard also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between Bard and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of September 30, 2018 , the Company is defending approximately 4,515 product liability claims involving Bard’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but claims are also pending in other state and/or federal court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Trials are scheduled throughout 2018 in the MDL and state courts. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. In January 2017, the Company reached an agreement to resolve litigation filed in the Southern District of New York by its insurance carriers in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage. Other Legal Matters In June 2007, Retractable Technologies, Inc. (“RTI”) filed a complaint against the Company under the caption Retractable Technologies, Inc. vs. Becton Dickinson and Company (Civil Action No. 2:07-cv-250, U.S. District Court, Eastern District of Texas) alleging that the BD Integra™ syringes infringe patents licensed exclusively to RTI. Included in its complaint, RTI also alleged that the Company engaged in false advertising with respect to certain of the Company’s safety-engineered products in violation of the Lanham Act; acted to exclude RTI from various product markets and to maintain its market share through, among other things, exclusionary contracts in violation of state and federal antitrust laws; and engaged in unfair competition. In January 2008, the Court severed the patent and non-patent claims into separate cases. BD paid a $5 million award following an adverse infringement verdict at the district court and the Company's unsuccessful appeal. On September 19, 2013, a jury returned a verdict against BD with respect to RTI’s Lanham Act claim and claim for attempted monopolization based on deception in the safety syringe market. The jury awarded RTI $113.5 million for its attempted monopolization claim (which would be trebled under the antitrust statute). Upon issuance of a Court of Appeals decision reversing the attempted monopolization claim, the Company recorded a $337 million reversal of reserves associated with the initial judgment, in Other operating (income) expense, net , in the first quarter of fiscal year 2017. The Court of Appeals affirmed the judgment for Lanham Act liability, and remanded the case to the district court to consider whether and if so how much profit should be disgorged by BD on that claim. The Court of Appeals also vacated and remanded the injunction ordered by the district court. On January 31, 2017, RTI filed a petition for a writ of certiorari with the U.S. Supreme Court. On March 20, 2017, the U.S. Supreme Court denied certiorari, and the district court thereafter heard RTI’s request for disgorgement. On August 17, 2017, the district court entered judgment in favor of BD and ruled that RTI is not entitled to any award of money damages. RTI has appealed this ruling to the Fifth Circuit Court of Appeals. Oral argument on the appeal occurred on October 3, 2018. Since early 2013, Bard has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In November 2015, the Department of Defense Inspector General issued an investigative subpoena to Bard. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the Company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. In July 2017, a separate civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec ® and QuantaFlo TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Reserves Accruals for the Bard product liability claims which are specifically discussed above, as well as the related legal defense costs, amounted to approximately $2.0 billion at September 30, 2018 . Such amounts include provisional estimates which have been recorded with respect to the acquired liabilities. These amounts may be adjusted upon the availability of new or additional information regarding facts or circumstances which existed at the acquisition date. As of September 30, 2018 , the Company has $94 million in Bard-related qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash . The Company's expected recoveries related to Bard-related product liability claims and related legal defense costs were approximately $343 million at September 30, 2018 . A substantial amount of these expected recoveries at September 30, 2018 relate to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The terms of the Company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the Company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2018 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

Segment Data

Segment Data	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Data	Segment Data Beginning in the second quarter of fiscal year 2018, the Company’s organizational structure was based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). As is further discussed in Note 9 , the Company completed its acquisition of Bard on December 29, 2017. Beginning in the second quarter of fiscal year 2018, the Interventional segment included the majority of Bard’s product offerings and certain product offerings, as further detailed below, which were previously reported in the Medical segment. Certain of Bard's product offerings were included under the Company's Medical segment, specifically within the new Medication Delivery Solutions unit, which was formerly the Medical segment's Medication and Procedural Solutions unit. The Company’s three principal business segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. BD Medical BD Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. BD Medical consists of the following organizational units: Organizational Unit Principal Product Lines Medication Delivery Solutions Peripheral IV catheters (conventional, safety), advanced peripheral catheters (guidewire assisted peripherally inserted venous catheters, midline catheters, port access), centeral lines (peripherally inserted centeral catheters), acute dialysis catheters; vascular access technology (ultrasonic imaging); vascular care (lock solutions, prefilled flush syringes, disinfecting caps); vascular preparation (skin antiseptics, dressings, securement); needle-free IV connectors and extensions sets, IV fluids; closed-system drug transfer devices, hazardous drug detection; conventional and safety hypodermic syringes and needles, anesthesia needles (spinal, epidural) and trays; enteral syringes, sharps disposal systems. Medication Management Solutions Intravenous medication safety and infusion therapy delivery systems, including infusion pumps and dedicated disposables; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; and analytics related to all the above products. Diabetes Care Syringes, pen needles and other products related to the injection or infusion of insulin and other drugs used in the treatment of diabetes. Pharmaceutical Systems Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems - provided to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations. BD Life Sciences BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections (“HAIs”) and cancers. In addition, BD Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; academic and government institutions; and pharmaceutical and biotechnology companies. BD Life Sciences consists of the following organizational units: Organizational Unit Principal Product Lines Preanalytical Systems Integrated systems for specimen collection; safety-engineered blood collection products and systems. Diagnostic Systems Automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; and plated media. Biosciences Fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; bench-side solutions for high-throughput targeted single-cell gene expression and RNA-Seq analysis; molecular indexing and next-generation sequencing sample preparation for genomics research; and clinical oncology, immunological (HIV) and transplantation diagnostic/monitoring reagents and analyzers. BD Interventional BD Interventional provides vascular, urology, oncology and surgical specialty products that are, with the exception of the V. Muller surgical and laparoscopic instrumentation products, intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by BD Interventional are hospitals, individual healthcare professionals, extended care facilities, alternate site facilities and directly to patients via the segment's Homecare business. The Interventional segment consists of the following organizational units: Organizational Unit Principal Product Lines Surgery Hernia and soft tissue repair, biological grafts, bioresorbable grafts, biosurgery, and other surgical products; BD ChloraPrep™ surgical infection prevention products, thoracic and abdominal drainage products and V. Mueller™ surgical & laparoscopic instrumentation products, which are products previously included within the former Medication and Procedural Solutions unit of BD Medical. Peripheral Intervention Percutaneous transluminal angioplasty (“PTA”) balloon catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug coated balloons, ports, biopsy, chronic dialysis, feeding, IVC filters, endovascular fistula creation devices and drainage products. Urology and Critical Care Urological drainage products, intermittent catheters, urinary and fecal management devices, kidney stone management devices, and Targeted Temperature Management. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. Segment operating income represents revenues reduced by product costs and operating expenses. Beginning with its first quarter fiscal year 2018, the Company changed its management reporting approach so that certain general and administrative costs, which were previously allocated to the segments, are now excluded from the segments' operating expenses. The Medical and Life Sciences segments' operating income for the year ended September 30, 2017 included allocated general corporate costs of $166 million and $113 million , respectively. The Medical and Life Sciences segments' operating income for the year ended September 30, 2016 included allocated general corporate costs of $175 million and $95 million , respectively. No such allocations were made in the year ended September 30, 2018 . As more fully discussed in Note 10 , the Company sold a 50.1% controlling financial interest in its Respiratory Solutions business, a component of the Medical segment, in October 2016. This transaction did not meet the criteria established for reporting discontinued operations and as such, results for the year ended September 30, 2016 included $822 million of revenues which did not occur in 2018 and 2017 . (Millions of dollars) 2018 2017 2016 Revenues (a) Medical (b) $ 8,616 $ 7,419 $ 7,965 Life Sciences 4,330 3,988 3,829 Interventional (b) 3,037 685 689 Total Revenues $ 15,983 $ 12,093 $ 12,483 Income Before Income Taxes Medical (b) (c) (d) $ 2,624 $ 1,907 $ 1,807 Life Sciences (e) 1,207 772 793 Interventional (b) (c) 306 248 245 Total Segment Operating Income 4,137 2,927 2,845 Acquisitions and other restructurings (744 ) (354 ) (728 ) Net interest expense (641 ) (445 ) (367 ) Other unallocated items (f) (1,578 ) (1,152 ) (676 ) Total Income Before Income Taxes $ 1,173 $ 976 $ 1,074 Assets Medical (b) $ 23,493 $ 15,552 $ 16,370 Life Sciences 4,225 4,056 3,848 Interventional (b) 23,219 2,780 2,784 Total Segment Assets 50,938 22,388 23,002 Corporate and All Other (g) 2,966 15,347 2,584 Total Assets $ 53,904 $ 37,734 $ 25,586 Capital Expenditures Medical (b) $ 560 $ 486 $ 464 Life Sciences 255 212 200 Interventional (b) 65 16 18 Corporate and All Other 14 13 12 Total Capital Expenditures $ 895 $ 727 $ 693 Depreciation and Amortization Medical (b) $ 1,028 $ 773 $ 801 Life Sciences 275 254 254 Interventional (b) 658 52 56 Corporate and All Other 17 10 3 Total Depreciation and Amortization $ 1,978 $ 1,088 $ 1,114 (a) The Company has no material intersegment revenues. (b) Prior-year amounts have been reclassified to reflect the movement of certain product offerings previously reported in the Medical segment and which are now reported in the Interventional segment, as further discussed above. Accordingly, all amounts presented in 2017 and 2016 for the Interventional segment are associated with these products. (c) The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million , respectively. (d) The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. (e) The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit. (f) The amounts in 2018 , 2017 and 2016 comprised of foreign exchange, corporate expenses, and share-based compensation expense. Results in 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves as further discussed in Note 5 . (g) Includes cash and investments and corporate assets. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe; Greater Asia (which includes Japan and Asia Pacific); and Other, which is comprised of Latin America, Canada, and EMA (which includes the Commonwealth of Independent States, Middle East and Africa). Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2018 2017 2016 Revenues United States $ 8,768 $ 6,504 $ 6,893 Europe 3,298 2,588 2,674 Greater Asia 2,460 1,744 1,692 Other 1,457 1,257 1,225 $ 15,983 $ 12,093 $ 12,483 Long-Lived Assets United States $ 38,982 $ 13,151 $ 14,075 Europe 5,640 4,421 3,747 Greater Asia 851 578 586 Other 645 584 483 Corporate 375 366 329 $ 46,494 $ 19,101 $ 19,220

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation The Company grants share-based awards under the 2004 Employee and Director Equity-Based Compensation Plan (“2004 Plan”), which provides long-term incentive compensation to employees and directors consisting of: stock appreciation rights (“SARs”), performance-based restricted stock units, time-vested restricted stock units and other stock awards. The fair value of share-based payments is recognized as compensation expense in net income. The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2018 2017 2016 Cost of products sold $ 36 $ 30 $ 29 Selling and administrative expense 136 113 106 Research and development expense 29 24 22 Acquisitions and other restructurings 130 10 39 $ 332 $ 177 $ 196 Tax benefit associated with share-based compensation costs recognized $ 79 $ 61 $ 69 Upon the Company's acquisition of Bard in 2018, certain pre-acquisition equity awards of Bard were converted into either BD SARs or BD restricted stock awards, as applicable. These awards have substantially the same terms and conditions as the converted Bard awards immediately prior to the acquisition date. The compensation expense of $126 million associated with these replacement awards was recorded in Acquisitions and other restructurings. Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs vest over a four -year period and have a ten -year term. The fair value was estimated on the date of grant using a lattice-based binomial option valuation model that uses the following weighted-average assumptions: 2018 2017 2016 Risk-free interest rate 2.32% 2.33% 2.17% Expected volatility 19.0% 20.0% 19.0% Expected dividend yield 1.33% 1.71% 1.76% Expected life 7.4 years 7.5 years 7.6 years Fair value derived $46.10 $33.81 $27.69 Expected volatility is based upon historical volatility for the Company’s common stock and other factors. The expected life of SARs granted is derived from the output of the lattice-based model, using assumed exercise rates based on historical exercise and termination patterns, and represents the period of time that SARs granted are expected to be outstanding. The risk-free interest rate used is based upon the published U.S. Treasury yield curve in effect at the time of grant for instruments with a similar life. The dividend yield is based upon the most recently declared quarterly dividend as of the grant date. The Company issued 1.4 million shares during 2018 to satisfy the SARs exercised. A summary of SARs outstanding as of September 30, 2018 and changes during the year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions of dollars) Balance at October 1 6,466 $ 117.94 Granted 4,295 123.97 Exercised (2,511 ) 98.67 Forfeited, canceled or expired (264 ) 163.69 Balance at September 30 7,986 $ 125.73 5.88 $ 1,080 Vested and expected to vest at September 30 7,732 $ 124.10 5.81 $ 1,059 Exercisable at September 30 5,450 $ 102.66 4.90 $ 863 A summary of SARs exercised 2018 , 2017 and 2016 is as follows: (Millions of dollars) 2018 2017 2016 Total intrinsic value of SARs exercised $ 333 $ 148 $ 148 Tax benefit realized from SAR exercises $ 90 $ 53 $ 52 Total fair value of SARs vested $ 107 $ 30 $ 24 Stock Options The Company has not granted stock options since 2005. Certain pre-acquisition equity awards of CareFusion were converted on March 17, 2015 into BD stock options with accelerated vesting terms and there were 166 thousand of these awards outstanding at September 30, 2018 . Amounts recognized or realized in 2018 , 2017 and 2016 relative to stock option exercises, including cash received, the tax benefit realized and the total intrinsic value, were immaterial to the Company’s consolidated financial results. Performance-Based and Time-Vested Restricted Stock Units Performance-based restricted stock units cliff vest three years after the date of grant. These units are tied to the Company’s performance against pre-established targets over a three -year performance period. The performance measures for fiscal years 2018 , 2017 and 2016 were relative total shareholder return (measures the Company’s stock performance during the performance period against that of peer companies) and average annual return on invested capital. Under the Company’s long-term incentive program, the actual payout under these awards may vary from zero to 200% of an employee’s target payout, based on the Company’s actual performance over the three -year performance period. The fair value is based on the market price of the Company’s stock on the date of grant. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of performance-related conditions. For units for which the performance conditions are modified after the date of grant, any incremental increase in the fair value of the modified units, over the original units, is recorded as compensation expense on the date of the modification for vested units, or over the remaining performance period for units not yet vested. Time-vested restricted stock unit awards granted after January 2015 vest on a graded basis over a three-year period. Time-vested restricted stock units granted before January 2015 cliff vest three years after the date of grant, except for certain key executives of the Company, including the executive officers, for which such units generally vest one year following the employee’s retirement. The related share-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all time-vested restricted stock units is based on the market value of the Company’s stock on the date of grant. A summary of restricted stock units outstanding as of September 30, 2018 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in thousands) Weighted Average Grant Date Fair Value Stock Units (in thousands) Weighted Average Grant Date Fair Value Balance at October 1 1,080 $ 161.64 2,136 $ 142.06 Granted 338 251.75 2,903 216.06 Distributed (119 ) 156.65 (1,368 ) 167.86 Forfeited or canceled (267 ) 173.67 (906 ) 178.87 Balance at September 30 1,032 (a) $ 190.57 2,765 $ 194.92 Expected to vest at September 30 548 (b) $ 192.35 2,585 $ 193.90 (a) Based on 200% of target payout. (b) Net of expected forfeited units and units in excess of the expected performance payout of 64 thousand and 420 thousand shares, respectively. The weighted average grant date fair value of restricted stock units granted during the years 2018 , 2017 and 2016 are as follows: Performance-Based Time-Vested 2018 2017 2016 2018 2017 2016 Weighted average grant date fair value of units granted $ 251.75 $ 174.92 $ 153.73 $ 216.06 $ 165.96 $ 145.57 The total fair value of stock units vested during 2018 , 2017 and 2016 was as follows: Performance-Based Time-Vested (Millions of dollars) 2018 2017 2016 2018 2017 2016 Total fair value of units vested $ 31 $ 32 $ 22 $ 362 $ 139 $ 114 At September 30, 2018 , the weighted average remaining vesting term of performance-based and time vested restricted stock units is 0.79 and 1.05 year, respectively. Unrecognized Compensation Expense and Other Stock Plans The amount of unrecognized compensation expense for all non-vested share-based awards as of September 30, 2018 , is approximately $307 million , which is expected to be recognized over a weighted-average remaining life of approximately 2.04 years. At September 30, 2018 , 7.1 million shares were authorized for future grants under the 2004 Plan. The Company has a policy of satisfying share-based payments through either open market purchases or shares held in treasury. At September 30, 2018 , the Company has sufficient shares held in treasury to satisfy these payments. As of September 30, 2018 , 135 thousand shares were held in trust relative to a Director's Deferral plan, which provides a means to defer director compensation, from time to time, on a deferred stock or cash basis. Also as of September 30, 2018 , 338 thousand shares were issuable under a Deferred Compensation Plan that allows certain highly-compensated employees, including executive officers, to defer salary, annual incentive awards and certain equity-based compensation.

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2018
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. Postretirement healthcare and life insurance benefits provided to qualifying domestic retirees as well as other postretirement benefit plans in international countries are not material. The measurement date used for the Company’s employee benefit plans is September 30. Effective January 1, 2018, the legacy U.S. pension plan was frozen to limit the participation of employees who are hired or re-hired by the Company, or who transfer employment to the Company, on or after January 1, 2018. Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2018 2017 2016 Service cost $ 136 $ 110 $ 81 Interest cost 90 61 72 Expected return on plan assets (154 ) (112 ) (109 ) Amortization of prior service credit (13 ) (14 ) (15 ) Amortization of loss 78 92 77 Settlements 2 — 7 Net pension cost $ 137 $ 138 $ 113 Net pension cost included in the preceding table that is attributable to international plans $ 34 $ 43 $ 35 The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. The settlement losses recorded in 2018 and 2016 primarily included lump sum benefit payments associated with the Company’s U.S. supplemental pension plan. The Company recognizes pension settlements when payments from the supplemental plan exceed the sum of service and interest cost components of net periodic pension cost associated with this plan for the fiscal year. The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2018 2017 Change in benefit obligation: Beginning obligation $ 2,647 $ 2,719 Service cost 136 110 Interest cost 90 61 Plan amendments — (1 ) Benefits paid (162 ) (123 ) Impact of acquisitions (divestitures) 758 (19 ) Actuarial gain (82 ) (134 ) Settlements (122 ) (1 ) Other, includes translation (19 ) 36 Benefit obligation at September 30 $ 3,246 $ 2,647 Change in fair value of plan assets: Beginning fair value $ 1,932 $ 1,855 Actual return on plan assets 70 134 Employer contribution 400 54 Benefits paid (162 ) (123 ) Impact of acquisitions (divestitures) 539 (13 ) Settlements (122 ) (1 ) Other, includes translation (15 ) 26 Plan assets at September 30 $ 2,642 $ 1,932 Funded Status at September 30: Unfunded benefit obligation $ (604 ) $ (715 ) Amounts recognized in the Consolidated Balance Sheets at September 30: Other $ 15 $ 9 Salaries, wages and related items (15 ) (17 ) Long-term Employee Benefit Obligations (604 ) (707 ) Net amount recognized $ (604 ) $ (715 ) Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30: Prior service credit $ 60 $ 74 Net actuarial loss (982 ) (1,065 ) Net amount recognized $ (921 ) $ (991 ) International pension plan assets at fair value included in the preceding table were $821 million and $678 million at September 30, 2018 and 2017 , respectively. The international pension plan projected benefit obligations were $1.064 billion and $917 million at September 30, 2018 and 2017 , respectively. The benefit obligation associated with postretirement healthcare and life insurance plans provided to qualifying domestic retirees, which was largely recorded to Long-Term Employee Benefit Obligations, was $148 million and $165 million at September 30, 2018 and 2017 , respectively. Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Obligation Exceeds the Fair Value of Plan Assets Projected Benefit Obligation Exceeds the Fair Value of Plan Assets (Millions of dollars) 2018 2017 2018 2017 Projected benefit obligation $ 2,618 $ 2,551 $ 3,121 $ 2,613 Accumulated benefit obligation $ 2,533 $ 2,470 Fair value of plan assets $ 2,012 $ 1,833 $ 2,502 $ 1,889 The estimated net actuarial loss and prior service credit for pension benefits that will be amortized from Accumulated other comprehensive income (loss) into net pension costs over the next fiscal year are expected to be $79 million and $14 million , respectively. The net actuarial loss for other postretirement benefits that will be amortized from Accumulated other comprehensive income (loss) into net other postretirement costs over the next fiscal year is immaterial. The estimated prior service credit that will be amortized from Accumulated other comprehensive income (loss) into net other postretirement costs over the next fiscal year is expected to be $5 million . The weighted average assumptions used in determining pension plan information were as follows: 2018 2017 2016 Net Cost Discount rate: U.S. plans (a) 3.71 % 3.42 % 4.15 % International plans 2.30 1.70 2.84 Expected return on plan assets: U.S. plans 7.20 7.25 7.50 International plans 4.95 4.65 5.02 Rate of compensation increase: U.S. plans 4.51 4.25 4.25 International plans 2.31 2.33 2.33 Benefit Obligation Discount rate: U.S. plans 4.26 3.72 3.42 International plans 2.30 2.25 1.70 Rate of compensation increase: U.S. plans 4.29 4.51 4.25 International plans 2.36 2.30 2.33 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. Expected Rate of Return on Plan Assets The expected rate of return on plan assets is based upon expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, the Company considers many factors, including historical assumptions compared with actual results; benchmark data; expected returns on various plan asset classes, as well as current and expected asset allocations. Expected Funding The Company’s funding policy for its defined benefit pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. The Company made discretionary contributions of $287 million to its U.S. pension plans in 2018. The Company also made a discretionary contribution of $200 million to its BD U.S. pension in October 2018. The Company does not anticipate any significant required contributions to its pension plans in 2019. Expected benefit payments are as follows: (Millions of dollars) Pension Plans Other Postretirement Benefits 2019 $ 213 $ 14 2020 202 14 2021 208 13 2022 209 13 2023 214 12 2024-2028 1,096 54 Investments The Company’s primary objective is to achieve returns sufficient to meet future benefit obligations. It seeks to generate above market returns by investing in more volatile asset classes such as equities while at the same time controlling risk through diversification in non-correlated asset classes and through allocations to more stable asset classes like fixed income. U.S. Plans The Company’s U.S. pension plans comprise 69% of total benefit plan investments, based on September 30, 2018 market values and have a target asset mix of 40% fixed income, 28% diversifying investments and 32% equities. This mix was established based on an analysis of projected benefit payments and estimates of long-term returns, volatilities and correlations for various asset classes. The asset allocations to diversifying investments include high-yield bonds, hedge funds, real estate, infrastructure, commodities, leveraged loans and emerging markets bonds. The actual portfolio investment mix may, from time to time, deviate from the established target mix due to various factors such as normal market fluctuations, the reliance on estimates in connection with the determination of allocations and normal portfolio activity such as additions and withdrawals. Rebalancing of the asset portfolio on a quarterly basis is required to address any allocations that deviate from the established target allocations in excess of defined allowable ranges. The target allocations are subject to periodic review, including a review of the asset portfolio’s performance, by the named fiduciary of the plans. Any tactical deviations from the established asset mix require the approval of the named fiduciary. The U.S. plans may enter into both exchange traded and non-exchange traded derivative transactions in order to manage interest rate exposure, volatility, term structure of interest rates, and sector and currency exposures within the fixed income portfolios. The Company has established minimum credit quality standards for counterparties in such transactions. The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2018 and 2017 . The categorization of fund investments is based upon the categorization of these funds’ underlying assets. (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Fixed Income: Mortgage and asset-backed securities $ 28 $ 155 $ — $ — $ — $ — $ 28 $ 155 $ — $ — Corporate bonds 484 232 — — 101 89 383 144 — — Government and agency-U.S. 257 107 — — 199 83 57 25 — — Government and agency-Foreign 122 98 8 12 85 63 28 22 — — Equity securities 536 369 360 307 176 62 — — — — Cash and cash equivalents 39 40 — — 39 40 — — — — Other 356 252 356 217 — 34 — — — — Fair value of plan assets $ 1,821 $ 1,254 $ 724 $ 537 $ 600 $ 371 $ 497 $ 346 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. Fixed Income Securities U.S. pension plan assets categorized above as fixed income securities include fund investments comprised of mortgage-backed, corporate, government and agency and asset-backed instruments. Mortgage-backed securities consist of residential mortgage pass-through certificates. Investments in corporate bonds are diversified across industry and sector and consist of investment-grade, as well as high-yield debt instruments. U.S. government investments consist of obligations of the U.S. Treasury, other U.S. government agencies, state governments and local municipalities. Assets categorized as foreign government and agency debt securities included investments in developed and emerging markets. The values of fixed income investments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. A portion of the fixed income instruments classified within Level 2 are valued based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. Equity Securities U.S. pension plan assets categorized as equity securities consist of fund investments in publicly-traded U.S. and non-U.S. equity securities. In order to achieve appropriate diversification, these portfolios are invested across market sectors, investment styles, capitalization weights and geographic regions. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Cash and Cash Equivalents A portion of the U.S. plans’ assets consists of investments in cash and cash equivalents, primarily to accommodate liquidity requirements relating to trade settlement and benefit payment activity, and the values of these assets are based upon quoted market prices. Other Securities Other U.S. pension plan assets include fund investments comprised of underlying assets of real estate, infrastructure, commodities and hedge funds. The values of such instruments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. International Plans International plan assets comprise 31% of the Company’s total benefit plan assets, based on market value at September 30, 2018 . Such plans have local independent fiduciary committees, with responsibility for development and oversight of investment policy, including asset allocation decisions. In making such decisions, consideration is given to local regulations, investment practices and funding rules. The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2018 and 2017 . (Millions of dollars) Total International Plan Asset Balances Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Significant Unobservable Inputs (Level 3) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Fixed Income: Corporate bonds $ 28 $ 14 $ — $ — $ 14 $ — $ 14 $ 13 $ — $ — Government and agency-U.S. 6 5 — — 3 1 3 3 — — Government and agency-Foreign 150 127 — — 104 83 46 45 — — Other fixed income 96 64 — — 63 57 33 7 — — Equity securities 314 256 15 13 299 242 — — — — Cash and cash equivalents 9 28 — — 9 28 — — — — Real estate 30 26 — — — — 30 26 — — Insurance contracts 114 98 — — — — — — 114 98 Other 74 62 — — 55 47 20 15 — — Fair value of plan assets $ 821 $ 678 $ 15 $ 13 $ 546 $ 459 $ 146 $ 108 $ 114 $ 98 (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. Fixed Income Securities Fixed income investments held by international pension plans include corporate, U.S. government and non-U.S. government securities. The values of fixed income securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Values of investments classified within Level 2 are based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources. Equity Securities Equity securities included in the international plan assets consist of publicly-traded U.S. and non-U.S. equity securities. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Other Securities The international plans hold a portion of assets in cash and cash equivalents, in order to accommodate liquidity requirements and the values are based upon quoted market prices. Real estate investments consist of investments in funds holding an interest in real properties and the corresponding values represent the estimated fair value based on the fair value of the underlying investment value or cost, adjusted for any accumulated earnings or losses. The values of insurance contracts approximately represent cash surrender value. Other investments include fund investments for which values are based upon either quoted market prices or market observable sources. The following table summarizes the changes, for the years ended September 30, 2018 and 2017 , in the fair value of international pension assets measured using Level 3 inputs: (Millions of dollars) Insurance Contracts Balance at September 30, 2016 $ 102 Actual return on plan assets: Relating to assets held at September 30, 2016 1 Purchases, sales and settlements, net (11 ) Transfers in from other categories 1 Exchange rate changes 4 Balance at September 30, 2017 $ 98 Actual return on plan assets: Relating to assets held at September 30, 2017 2 Purchases, sales and settlements, net 15 Transfers in from other categories 1 Exchange rate changes (2 ) Balance at September 30, 2018 $ 114 Defined Contribution Plans The Company has voluntary defined contribution plans covering eligible employees in the United States which provide for a Company match as well as a Company contribution for Bard associates and for associates hired or rehired after December 31, 2017. The cost of these plans was $89 million in 2018 , $67 million in 2017 and $61 million in 2016 . The 2018 increase in the cost associated with these plans is attributable to the Company's acquisition of Bard.

Acquisitions

Acquisitions	12 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions Bard On December 29, 2017, the Company completed its acquisition of Bard, to create a medical technology company which is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers. Under the terms of the transaction, Bard common shareholders received approximately $222.93 in cash and 0.5077 shares of BD stock per Bard share. The Company financed the cash portion of total consideration transferred with available cash, which included net proceeds raised in the third quarter of fiscal year 2017 through registered public offerings of equity securities and debt transactions of approximately $4.8 billion and $9.6 billion , respectively. The operating activities of Bard from the acquisition date through December 31, 2017 were not material to the Company’s consolidated results of operations. As such, Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. The acquisition-date fair value of consideration transferred consisted of the components below. The fair value of the shares and equity awards issued as consideration was recognized as a $6.5 billion increase to Capital in excess of par value and a $2.1 billion decrease to Common stock in treasury. (Millions of dollars) Cash consideration $ 16,400 Non-cash consideration-fair value of shares issued 8,004 Non-cash consideration-fair value of equity awards issued 613 Total consideration transferred $ 25,017 The acquisition-date fair value of the Company’s ordinary shares issued to Bard shareholders was calculated per the following (shares in millions): (Millions of dollars, except per share data) Total Bard shares outstanding 73.359 Conversion factor 0.5077 Conversion of Bard shares outstanding 37.243 Conversion of pre-acquisition equity awards 0.104 Total number of the Company's share issued 37.347 Closing price of the Company’s stock $ 214.32 Fair value of the Company’s issued shares $ 8,004 Allocation of Consideration Transferred to Net Assets Acquired As discussed in Note 6 , the majority of Bard's product offerings are reported, beginning with the second quarter of fiscal year 2018, under the Interventional segment and Bard's remaining product offerings are reported under the Company's Medical segment. The acquisition was accounted for under the acquisition method of accounting for business combinations. The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The preliminary allocations of the purchase price below provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates will be adjusted upon the availability of further information regarding events or circumstances which existed at the acquisition date and such adjustments may be significant. The assets acquired and liabilities assumed in this acquisition, as recorded in the Company's consolidated balance sheet at September 30, 2018 , were largely allocated to the Company's new Interventional segment. (Millions of dollars) Cash and equivalents $ 1,480 Trade receivables 472 Inventories 974 Property, plant and equipment 553 Developed technology 10,469 Customer relationships 1,146 Other assets 624 Total identifiable assets acquired 15,718 Payables, accrued expenses and other liabilities 1,276 Short term and long-term debt 1,692 Product liability and other legal reserves 2,029 Deferred tax liabilities 1,713 Total liabilities assumed 6,711 Net identifiable assets acquired 9,007 Goodwill 16,009 Net assets acquired $ 25,017 Identifiable Intangible Assets Acquired The developed technology assets acquired represented Bard’s developed technologies in the fields of vascular, urology, oncology, and surgical specialties. The technologies’ fair values were determined based on the present value of projected cash flows utilizing an income approach with a risk-adjusted discount rate of 8% . The technologies will be amortized over an estimated weighted-average amortization period of 14 years , which is the weighted average period over which the technologies are expected to generate substantial cash flows. The customer relationships assets acquired represented Bard’s relationships with its customers. The fair value of these customer relationships was determined based on the present value of projected cash flows utilizing an income approach with a risk-adjusted discount rate of 8% . The estimated weighted-average amortization period of the customer relationships was determined to be 13 years and this period corresponds with the weighted average of lives determined for the product technology which underlies the customer contracts. Goodwill Goodwill typically results through expected synergies from combining operations of the acquiree and the acquirer, as well as from intangible assets that do not qualify for separate recognition. The goodwill recognized as a result of this acquisition includes, among other things, the value of combining the Company's leadership in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard's strong product portfolio and innovation pipeline are expected to increase the Company's opportunities in fast-growing clinical areas. Revenue synergies are also expected to result from enhanced growth opportunities for the combined company in non-U.S. markets. No portion of goodwill from this acquisition was deductible for tax purposes. Amounts Related to Bard's Legal Proceedings and Claims Accruals for Bard-related product liability and other legal matters represented approximately $2.0 billion of the liabilities assumed. Cash and equivalents include a restricted cash balance acquired which largely represents funds that are restricted for certain product liability matters assumed. Additional disclosures regarding Bard's legal proceedings and claims are provided in Note 5 . The Tax Cuts and Job Act Transition Tax The net assets acquired included approximately $175 million of transition tax payable based on the Company’s best estimate of its transition tax liability under new U.S. tax legislation which is further discussed in Note 16 . Transaction Costs Transaction costs related to this acquisition incurred during the years ended September 30, 2018 and 2017 were approximately $56 million and $25 million , respectively. These transaction costs were recorded as Acquisitions and other restructurings and consisted of legal, advisory and other costs. See Note 11 for discussion regarding restructuring costs incurred relative to the Bard acquisition in 2018 . Unaudited Pro Forma Information As noted above, Bard's operating activities from the acquisition date through December 31, 2017 were not material and the Company included Bard in its consolidated results of operations beginning on January 1, 2018. Revenues in 2018 were $3 billion . Net Income in 2018 included loss attributable to Bard of $(107) million . The following table provides the pro forma results for the fiscal years 2018 and 2017 as if Bard had been acquired as of October 1, 2016. (Millions of dollars, except per share data) 2018 2017 Revenues $ 16,947 $ 15,781 Net Income $ 390 $ 1,145 Diluted Earnings per Share $ 0.90 $ 3.60 The pro forma results above include the impact of the following adjustments, as necessary: additional amortization and depreciation expense relating to assets acquired; interest and other financing costs relating to the acquisition transaction; and the elimination of one-time or nonrecurring items. The one-time or nonrecurring items eliminated for the year ended September 30, 2018 were primarily comprised of fair value step-up adjustments of $478 million recorded relative to Bard's inventory on the acquisition date, the transaction costs discussed above, as well as certain Bard-related restructuring costs disclosed in Note 11 . In addition, amounts previously reported by Bard as revenues related to a royalty income stream have been reclassified to Other income (expense), net to conform to the Company's reporting classification. The pro forma results do not include any anticipated cost savings or other effects of the planned integration of Bard. Accordingly, the pro forma results above are not necessarily indicative of the results that would have been if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future. Other Transactions During the fourth quarter of fiscal year 2018, the Company acquired TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis. This acquisition did not materially impact the Company's consolidated financial results. The Company has completed various other acquisitions during fiscal year 2018 which were not material individually or in the aggregate. Upon the Company's acquisition of CareFusion, it acquired a 40% ownership interest in Caesarea Medical Electronics ("CME"), an Israeli-based global infusion pump systems manufacturer. The Company previously accounted for this interest as an equity investment. On April 3, 2017, the Company acquired the remaining 60% ownership interest in CME. This acquisition did not materially impact the Company's consolidated financial results.

Divestiture

Divestiture	12 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestiture Advanced Bioprocessing The Company completed the sale of its Advanced Bioprocessing business in October 2018 per a definitive agreement that was signed in September 2018. Assets held for sale on the consolidated balance sheet at September 30, 2018 , subject to this agreement, were approximately $137 million . Liabilities held for sale under the agreement were immaterial. The Company estimates that its gross cash proceeds received will be approximately $475 million , subject to post-closing adjustments. The historical financial results for the Advanced Bioprocessing business, which included approximately $106 million , $103 million and $95 million of revenues for the years ended September 30, 2018 , 2017 and 2016 , respectively, have not been classified as a discontinued operation. Respiratory Solutions and Vyaire Medical On October 3, 2016, the Company sold a 50.1% controlling financial interest in its Respiratory Solutions business, a component of the Medical segment, to form a venture, Vyaire Medical. The Company retained a 49.9% non-controlling interest in the new standalone entity. The Company agreed to various contract manufacturing and certain logistical and transition services agreements with the new entity for a period of up to two years after the sale. The Company accounted for its remaining interest in the new entity as an equity method investment and recorded its share of the new entity's earnings or losses on a one-quarter lag to Other income (expense), net . In April 2018, the Company completed the sale of its remaining interest in Vyaire Medical. The Company received gross cash proceeds of approximately $435 million and recognized a pre-tax gain on the sale of approximately $303 million , which was recognized in Other income (expense), net .

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Business Restructuring Charges	Business Restructuring Charges In connection with the Company's acquisition of Bard, the 2015 acquisition of CareFusion and other portfolio rationalization initiatives, the Company incurred restructuring costs which were recorded as Acquisitions and other restructurings . Additional disclosures regarding these restructuring activities and the related costs are provided in Notes 7 , 9 and 10 . Restructuring liability activity in 2018 , 2017 and 2016 was as follows: Employee Termination Other Total (Millions of dollars) Bard CareFusion/Other Initiatives (a) Bard (b) CareFusion/Other Initiatives (c) Bard CareFusion/Other Initiatives Balance at September 30, 2015 $ — $ 62 $ — $ — $ — $ 62 Charged to expense — 81 — 445 — 526 Cash payments — (76 ) — (72 ) — (148 ) Non-cash settlements — — — (39 ) — (39 ) Other adjustments — — — (332 ) — (332 ) Balance at September 30, 2016 $ — $ 67 $ — $ 2 $ — $ 69 Charged to expense — 27 — 58 — 85 Cash payments — (45 ) — (12 ) — (57 ) Non-cash settlements — — — (9 ) — (9 ) Other adjustments — — — (33 ) — (33 ) Balance at September 30, 2017 $ — $ 49 $ — $ 6 $ — $ 55 Charged to expense 136 30 156 22 292 52 Cash payments (103 ) (56 ) (3 ) (23 ) (106 ) (79 ) Non-cash settlements — — (153 ) (1 ) (153 ) (1 ) Other adjustments — — — — — — Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 (a) Expenses in fiscal year 2016 included $40 million relating to the CareFusion acquisition as well as $13 million for employee termination costs resulting from the Company's transition of certain elements of its information technology function to an outsourced model as further disclosed below. (b) Expenses in 2018 represented the cost associated with the conversion of certain pre-acquisition equity awards of Bard to BD equity awards as well as costs relating to Bard’s pension plan, partially offset by a gain on the sale of the Company's soft tissue core needle biopsy product line which was recorded in the second quarter of fiscal year 2018. (c) Expenses in 2016 included $214 million non-cash charge to recognize the impairment of capitalized internal-use software assets held for sale upon the Company’s decision to transition certain business information systems assets to a third party. Expenses in 2016 also included non-cash impairment charges of $81 million , after-tax, relating to the Company's disposition of certain non-core businesses, including the Company's sale of a majority interest in its Respiratory Solutions business during the first quarter of fiscal year 2017, which is further discussed in Note 10 .

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets at September 30 consisted of: 2018 2017 (Millions of dollars) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets Developed technology $ 13,966 $ 1,782 $ 3,508 $ 1,029 Customer relationships 4,584 861 3,393 564 Product rights 121 58 131 54 Trademarks 407 84 408 65 Patents and other 397 288 370 274 Amortized intangible assets $ 19,475 $ 3,073 $ 7,811 $ 1,986 Unamortized intangible assets Acquired in-process research and development $ 37 $ 67 Trademarks 2 2 Unamortized intangible assets $ 39 $ 69 Additional disclosures regarding the increases to the developed technology assets and customer relationships as a result of the Bard acquisition are provided in Note 9 . Intangible amortization expense was $1.255 billion , $0.533 billion and $0.552 billion in 2018 , 2017 and 2016 , respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2019 to 2023 are as follows: 2019 — $1.472 billion ; 2020 — $1.350 billion ; 2021 — $1.347 billion ; 2022 — $1.338 billion ; 2023 — $1.333 billion . The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2016 $ 6,688 $ 731 $ — $ 7,419 Acquisitions (a) 119 24 — 143 Divestiture (b) (25 ) — — (25 ) Purchase accounting adjustments 4 — — 4 Currency translation 16 6 — 22 Goodwill as of September 30, 2017 $ 6,802 $ 761 $ — $ 7,563 Acquisitions (c) 3,923 76 11,218 15,217 Divestiture (b) — (59 ) (57 ) (116 ) Reallocation of goodwill for change in segment and reporting unit composition (d) (877 ) — 877 — Purchase accounting adjustments (e) 228 (2 ) 732 959 Currency translation (22 ) (2 ) — (24 ) Goodwill as of September 30, 2018 $ 10,054 $ 775 $ 12,771 $ 23,600 (a) Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (b) Represents goodwill derecognized upon the Company's sale of certain businesses, as further discussed in Note 10 . (c) Represents goodwill primarily recognized upon the Company's acquisition of Bard in fiscal year 2018, which is further discussed in Note 9 . Also includes goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (d) Represents the reassignment of goodwill, determined based upon a relative fair value allocation approach, associated with the movement of certain product offerings which were previously reported in the Medical segment and which are now reported in the Interventional segment as further discussed in Note 6 . (e) The purchase accounting adjustments increasing goodwill were primarily driven by the valuation of Bard developed technology assets, the associated deferred tax liability changes, increases to legal reserves and the alignment of the combined organization's accounting policies with respect to accrued liabilities and other accounts.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts and currency options. Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other income (expense), net , during the years ending September 30, 2018 , 2017 and 2016 were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of September 30, 2018 and 2017 were $3.1 billion and $2.5 billion , respectively. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has designated $2.7 billion of Euro-denominated debt and $324 million of British Pound-denominated debt as net investment hedges. Accordingly, net gains or losses relating to this debt, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss) . The Company has recorded net gains (losses) relating to these net investment hedges of $81 million and $(159) million to Accumulated other comprehensive income (loss) as of September 30, 2018 and 2017 , respectively. Additional disclosures regarding the Company's issuances of the Euro-denominated debt and British Pound-denominated in fiscal year 2018 are provided in Note 15 . Interest Rate Risks and Related Strategies The Company’s primary interest rate exposure results from changes in U.S. dollar interest rates. The Company’s policy is to manage interest cost using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are offset by amounts recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million , net of tax. The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $1.2 billion and $375 million at September 30, 2018 and 2017 , respectively. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the years ended September 30, 2018 and 2017 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results. Other Risk Exposures The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company had no outstanding commodity derivative forward contracts at September 30, 2018 and 2017 . Financial Statement Effects Effects on Consolidated Balance Sheets The fair values of derivative instruments outstanding at September 30, 2018 and 2017 were not material to the Company's consolidated balance sheets. Effects on Consolidated Statements of Income The amounts recognized from other comprehensive income relating to cash flow hedges during 2018 , 2017 and 2016 were not material to the Company's consolidated financial results.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The Company’s institutional money market accounts permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair values of these accounts were $228 million and $2.026 billion at September 30, 2018 and 2017 , respectively. The Company’s remaining cash and equivalents, excluding restricted cash, were $913 million and $12.153 billion at September 30, 2018 and 2017 , respectively. Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The cash equivalents consist of liquid investments with a maturity of three months or less and the short-term investments consist of instruments with maturities greater than three months and less than one year . Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $18.8 billion and $19.2 billion at September 30, 2018 and 2017 , respectively. The fair value of the current portion of long-term debt was $1.893 billion and $206 million at September 30, 2018 and 2017 , respectively. All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets. Nonrecurring Fair Value Measurements In fiscal year 2018, the Company recorded charges of $58 million to write down the value of fixed assets, primarily in the Diabetes Care unit, as well as charges of $81 million to write down the carrying value of certain intangible and other assets in the Biosciences unit. In fiscal year 2016, the Company recorded a charge to Acquisitions and other restructurings of $214 million to impair capitalized internal-use software assets held for sale as a result of the Company's transition of certain elements of its information technology infrastructure to an outsourced model. Also in fiscal year 2016, the Company recorded losses of $81 million on the held for sale assets of certain non-core businesses. The amounts recognized in 2018 and 2016 were recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using either Level 2 inputs, including quoted prices for similar assets, or Level 3 inputs, including values estimated using the income approach. Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity.

Debt

Debt	12 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt Short-term debt Short-term debt at September 30 consisted of: (Millions of dollars) 2018 2017 Current portion of long-term debt 2.133% Notes due June 6, 2019 724 — 0.368% Notes due June 6, 2019 (a) 1,157 — 4.900% Notes due April 15, 2018 — 200 Term Loan Facility due September 5, 2019 (b) 710 — Other 10 3 Total short-term debt $ 2,601 $ 203 (a) Includes notes issued during fiscal year 2018, as further discussed below. (b) Term loan facility entered into during the fourth quarter of fiscal year 2018, as further discussed below. The weighted average interest rates for short-term debt were 1.58% and 4.90% at September 30, 2018 and 2017 , respectively. Long-term debt Long-Term Debt at September 30 consisted of: (Millions of dollars) 2018 2017 2.133% Notes due June 6, 2019 $ — $ 723 0.368% Notes due June 6, 2019 — 823 2.675% Notes due December 15, 2019 1,123 1,121 2.404% Notes due June 5, 2020 998 996 3.250% Notes due November 12, 2020 699 698 Floating Rate Notes due December 29, 2020 (a) 996 — 3.125% Notes due November 8, 2021 990 1,003 2.894% Notes due June 6, 2022 1,793 1,791 Floating Rate Notes due June 6, 2022 498 497 1.000% Notes due December 15, 2022 576 586 3.300% Notes due March 1, 2023 296 296 1.401% Notes due May 24, 2023 (a) 346 — 3.875% Notes due May 15, 2024 182 182 3.363% Notes due June 6, 2024 1,738 1,736 3.734% Notes due December 15, 2024 1,368 1,367 3.020% Notes due May 24, 2025 (a) 324 — 6.700% Notes due December 1, 2026 (b) 177 — 1.900% Notes due December 15, 2026 575 585 3.700% Notes due June 6, 2027 2,383 2,381 7.000% Debentures due August 1, 2027 156 166 6.700% Debentures due August 1, 2028 154 164 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 296 296 4.875% Notes due May 15, 2044 331 331 4.685% Notes due December 15, 2044 1,159 1,189 4.669% Notes due June 6, 2047 1,484 1,484 Other long-term debt 8 3 Total Long-Term Debt $ 18,894 $ 18,667 (a) Includes notes issued during fiscal year 2018, as further discussed below. (b) Includes notes assumed in connection with the Company's acquisition of Bard, as further discussed below. The aggregate annual maturities of debt including interest during the fiscal years ending September 30, 2019 to 2023 are as follows: 2019 — $3.3 billion ; 2020 — $2.8 billion ; 2021 — $2.3 billion ; 2022 — $3.8 billion ; 2023 — $1.7 billion . Other current credit facilities In connection with the Company's agreement to acquire Bard, the Company entered into a three -year senior unsecured term loan facility of $2.25 billion during the third quarter of fiscal year 2017. During the first quarter of fiscal year 2018, the proceeds from this facility were used to fund a portion of the cash consideration for the Bard acquisition, as well as the fees and expenses incurred in connection with the acquisition. In September 2018, the Company entered into a 364 -day $750 million senior unsecured term loan facility. The Company used $230 million of proceeds drawn from this facility in September 2018 to repay all borrowings outstanding under the three -year term loan facility discussed above. Borrowings outstanding under the new, 364 -day term loan facility were $710 million at September 30, 2018 . The Company also entered into a five -year senior unsecured revolving credit facility in the third quarter of fiscal year 2017 which became effective upon the closing of the Bard acquisition and which provides borrowing of up to $2.25 billion . This facility will expire in December 2022 and replaced the $1.5 billion syndicated credit facility the Company previously had in place for general corporate purposes. Under the new revolving facility, the Company will be able to issue up to $100 million in letters of credit under this new revolving credit facility and it also includes a provision that enables the Company, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2.75 billion . There were no borrowings outstanding under the revolving credit facility at September 30, 2018 . In addition, the Company has informal lines of credit outside of the United States. Exchange of Bard Notes Also in connection with the Company's acquisition of Bard, the Company exchanged certain outstanding notes issued by Bard for a like-amount of new notes issued by the Company. The exchange offers, which were conditioned upon the closing of the Bard acquisition, expired on December 29, 2017. The aggregate principal amounts of Bard notes which were validly tendered for notes issued by the Company are provided below. (Millions of dollars) Interest Rate and Maturity Aggregate Principal Amount Principal Amount Accepted for Exchange 4.400% Notes due January 15, 2021 $ 500 $ 432 3.000% Notes due May 15, 2026 500 470 6.700% Notes due December 1, 2026 150 137 Total $ 1,150 $ 1,039 This exchange transaction was accounted for as a modification of the assumed debt instruments. Following the exchange of the notes, the aggregate principal amount of Bard notes that remained outstanding after settlement of the exchange transaction was $111 million . 2018 Debt-Related Transactions In January 2018, the Company commenced an offer to repurchase any and all of the outstanding 3.000% Notes due May 15, 2026 that were issued as a result of the exchange transaction discussed above. Under the terms of the repurchase offer, holders were entitled to receive cash equal to 101% of the principal amount of notes validly tendered, plus accrued and unpaid interest, if any, to the date of purchase. The offer to repurchase the 3.000% Notes expired on March 1, 2018 and a total of $461 million aggregate principal amount of notes were validly tendered at a market price of $465 million . Based upon the carrying value of $452 million , the Company recorded a loss relating to this debt extinguishment in the second quarter of fiscal year 2018 of $13 million as Other income (expense), net , on its consolidated statements of income. During the second quarter of fiscal year 2018, the Company issued Euro-denominated debt consisting of 300 million Euros ( $370 million ) of 0.368% notes due June 6, 2019 under an indenture pursuant to which the Company previously issued, in the third quarter of fiscal year 2017, 0.368% notes due June 6, 2019. Also in the second quarter of fiscal year 2018, the Company issued $1 billion of floating rate senior unsecured U.S. notes due December 29, 2020. The Company used the net proceeds from these long-term debt offerings to repay portions of the balances outstanding on its term loan and revolving credit facilities, which are discussed above, as well as accrued interest, related premiums, fees and expenses related to these repaid amounts. In June 2018, the Company redeemed all of the 4.400% Notes due January 15, 2021 and 3.000% Notes due May 15, 2026 which were issued by Bard and that remained outstanding after the exchange offer discussed further above. Also in June 2018, the Company redeemed all of the 4.400% Notes due January 15, 2021 which were issued by the Company upon the exchange offer, as well as all of the 3.000% Notes due May 15, 2026 issued by the Company which remained outstanding after the repurchase offer also discussed above. The total aggregate principal amount of notes redeemed was $539 million . Based upon the $556 million carrying value of these notes and the $559 million the Company paid to redeem the aggregate principal amount of the notes, the Company recorded a loss on these debt extinguishment transactions in the third quarter of fiscal year 2018 of $3 million as Other income (expense), net , on its consolidated statements of income. During the third quarter of fiscal year 2018, the Company issued Euro-denominated debt consisting of 300 million Euros ( $354 million ) of 1.401% notes due May 24, 2023. Also in the third quarter of fiscal year 2018, the Company issued British Pound-denominated debt of 250 million British Pounds ( $337.5 million ) of 3.02% notes due May 24, 2025. The Company used the net proceeds from these long-term debt offerings to redeem certain notes in the third quarter, as further discussed above, and to repay a portion of the balance outstanding on its term loan, as well as accrued interest, related premiums, fees and expenses related to this repaid amount. 2017 Debt-Related Transactions In December 2016, the Company issued euro-denominated debt consisting of 500 million Euros of 1.000% notes and 500 million Euros of 1.900% notes. The Company used the net proceeds from this long-term debt offering, together with other sources of liquidity, to fund the Company's repurchase of certain of its senior notes outstanding. Under this cash tender offer, the Company repurchased all or a portion of the aggregate principal amounts of certain of its long-term notes outstanding, totaling $1.689 billion , at an aggregate market price of $1.764 billion . The carrying value of these long-term notes was $1.727 billion , and the Company recognized a loss on this debt extinguishment of $42 million , which was recorded in December 2016 as Other income (expense), net , on the Company’s consolidated statements of income. During the third quarter of 2017 and in connection with the Company's acquisition of Bard, as previously discussed in Note 9, the Company issued senior unsecured U.S. notes with an aggregate principal amount of $9.675 billion . Also during the third quarter of 2017, the Company issued Euro-denominated debt consisting of 700 million Euros of 0.368% Notes due June 6, 2019. Also in 2017, the Company redeemed all or a portion of the aggregate principal amounts of certain of its long-term senior notes outstanding, totaling $1.717 billion , at an aggregate market price of $1.776 billion . The carrying value of these long-term notes was $1.745 billion and the Company recognized a loss on this debt extinguishment of $31 million , which was recorded in June 2017 as Other income (expense), net , on the Company’s consolidated statements of income. Capitalized interest The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2018 2017 2016 Charged to operations $ 706 $ 521 $ 388 Capitalized 42 32 30 Total interest costs $ 748 $ 553 $ 418 Interest paid, net of amounts capitalized $ 674 $ 435 $ 392

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes New U.S. Tax Legislation New U.S. tax legislation, which is commonly referred to as the Tax Cuts and Job Act (the "Act") and which was enacted on December 22, 2017, reduces the U.S. federal corporate tax rate from 35% to 21% , requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign-sourced earnings. Under U.S. generally accepted accounting principles, companies must account for the effects of changes in income tax rates and laws in the period in which the legislation is enacted. However, the U.S. Securities and Exchange Commission (the "SEC") has provided guidance which allows companies to report financial results including provisional amounts that have been recorded for the income tax effects of the Act based upon a reasonable estimate of those effects. The SEC expects that accounting for the Act should be completed by companies by no later than one year from the enactment date of the Act. As of September 30, 2018 , the Company has not completed its accounting for the tax effects of enactment of the Act; however, the Company has made what it believes is a reasonable estimate of the effects on the remeasurement of U.S. deferred tax balances, the one-time transition tax, and the taxes accrued relating to the change in permanent reinvestment assertion for unremitted earnings of its foreign subsidiaries. As a result of these estimates, the Company recognized a provisional expense in the amount of $640 million , which is reflected in the Company's consolidated statement of income within Income tax provision . The Company also recorded a charge, which is further discussed below, relating to historic unremitted foreign earnings as of September 30, 2018 . The Company will continue to gather information and perform additional analysis on these estimates, including, but not limited to, the amount of earnings and profits subject to the transition tax, the calculation of foreign tax credits, the local tax treatment of future distributions of unremitted earnings and the remeasurement of U.S. deferred taxes. Any measurement period adjustments will be reported as a component of Income tax provision in the reporting period the amounts are determined. The final accounting will be completed no later than one year from the enactment of the Act. The Company is currently in the process of evaluating the new Global Intangible Low-Taxed Income’s ("GILTI") provisions and has not yet elected an accounting policy regarding whether to record deferred taxes related to GILTI. Therefore, the Company has not made any adjustments related to the GILTI tax in its financial statements. Under the SEC guidance noted above, the Company will continue to analyze and assess the effects of the GILTI provisions of the Act. Provisional Amounts The Company believes that all provisional amounts reflected in its financial statements are based on the best estimates that can be made at this time. The Company will continue to analyze all impacts of the Act and will update provisional amounts as required. Deferred tax assets and liabilities The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21% . However, the Company is still analyzing certain aspects of the Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The Company recorded a provisional tax benefit of $182 million related to the re-measurement of the Company's deferred tax balances. Foreign tax effects The one-time transition tax is based on the Company's total post-1986 earnings and profits ("E&P") that the Company previously deferred from U.S. income taxes. The Company recorded a provisional amount for its one-time transition tax liability for all of its foreign subsidiaries, resulting in an increase in income tax expense of $822 million . However, the Company has not yet completed its calculation of the total post-1986 E&P for these foreign subsidiaries. Further, the transition tax is based in part on the amount of those earnings held in cash and other specified assets. This amount may change when the Company finalizes the calculation of post-1986 foreign E&P previously deferred from U.S. federal taxation and finalizes the amounts held in cash or other specified assets. As discussed in Note 9, the Company completed its acquisition of Bard on December 29, 2017. The net assets acquired included approximately $175 million of transition tax payable based on the Company's best estimate of its transition tax liability. The combined company's transition tax liability, 8% of which is payable per year over the next five years with the balance payable over the following three years, is approximately $1 billion . The anticipated payment of this tax is expected to begin on January 15, 2019. The Company has historically asserted indefinite reinvestment of the earnings of certain non-U.S. subsidiaries outside the United States. The Act eliminated certain material tax effects on the repatriation of cash to the United States. Future repatriation of cash and other property held by our foreign subsidiaries will generally not be subject to U.S. federal income tax. As a result, after reevaluation of the permanent reinvestment assertion, the Company is no longer permanently reinvested with respect to its historic unremitted foreign earnings as of September 30, 2018. As a result of the change in the assertion, during fiscal 2018, the Company recorded a charge of $134 million to Income tax provision related to historic unremitted foreign earnings as of September 30, 2018 . Provision for Income Taxes The provision for income taxes the years ended September 30 consisted of: (Millions of dollars) 2018 2017 2016 Current: Federal $ 665 $ (230 ) $ 312 State and local, including Puerto Rico 73 (20 ) 17 Foreign 387 200 286 $ 1,124 $ (50 ) $ 616 Deferred: Domestic $ (201 ) $ (64 ) $ (441 ) Foreign (61 ) (10 ) (78 ) (262 ) (74 ) (519 ) Income tax provision (benefit) $ 862 $ (124 ) $ 97 The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2018 2017 2016 Domestic, including Puerto Rico $ (135 ) $ (386 ) $ (232 ) Foreign 1,308 1,362 1,306 Income Before Income Taxes $ 1,173 $ 976 $ 1,074 Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that certain audits will close within the next twelve months but no significant increases or decreases in the amount of the unrecognized tax benefits are expected to result. (Millions of dollars) 2018 2017 2016 Balance at October 1 $ 349 $ 469 $ 593 Increase due to acquisitions 140 — — Increase due to current year tax positions 43 41 81 Increase due to prior year tax positions 43 19 10 Decreases due to prior year tax positions — (30 ) (3 ) Decrease due to settlements with tax authorities (29 ) (145 ) (147 ) Decrease due to lapse of statute of limitations (3 ) (5 ) (65 ) Balance at September 30 $ 543 $ 349 $ 469 Upon the Company's acquisition of CareFusion in 2015, the Company became a party to a tax matters agreement with Cardinal Health resulting from Cardinal Health's spin-off of CareFusion in fiscal year 2010. Under the tax matters agreement, the Company is obligated to indemnify Cardinal Health for certain tax exposures and transaction taxes prior to CareFusion’s spin-off from Cardinal Health. The indemnification payable is approximately $140 million at September 30, 2018 and is included in Deferred Income Taxes and Other on the consolidated balance sheet. At September 30, 2018 , 2017 and 2016 , there are $632 million , $415 million and $478 million of unrecognized tax benefits that if recognized, would affect the effective tax rate. During the fiscal years ended September 30, 2018 , 2017 and 2016 , the Company reported interest and penalties associated with unrecognized tax benefits of $20 million , $57 million and $(38) million on the consolidated statements of income as a component of Income tax provision . The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. The IRS has completed its audit for the BD Legacy fiscal year 2014 and combined company fiscal years 2016 and 2017. For the BD legacy business, all years are effectively settled with the exception of 2015 for which the Company believes it is adequately reserved for any potential exposures. The IRS is currently examining the CareFusion legacy fiscal year 2014 and short period 2015. With the exception of the CareFusion legacy fiscal year 2010 audit, all other periods are at various stages of appeals or protests. With regard to Bard, all examinations have been completed through calendar year 2014. The IRS has commenced the examination of calendar years 2015 and 2016. For the other major tax jurisdictions where the Company conducts business, tax years are generally open after 2012 . Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2018 2017 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 458 $ — $ 618 $ — Property and equipment — 253 — 244 Intangibles — 2,948 — 1,584 Loss and credit carryforwards 1,290 — 1,098 — Other 707 384 531 164 2,455 3,585 2,247 1,992 Valuation allowance (1,181 ) — (1,032 ) — Net (a) $ 1,275 $ 3,585 $ 1,216 $ 1,992 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other on the consolidated balance sheets . Deferred tax assets and liabilities are netted on the balance sheet by separate tax jurisdictions. Deferred taxes have been provided on undistributed earnings of foreign subsidiaries as of September 30, 2018. Generally, deferred tax assets have been established as a result of net operating losses and credit carryforwards with expiration dates from 2019 to an unlimited expiration date. Valuation allowances have been established as a result of an evaluation of the uncertainty associated with the realization of certain deferred tax assets on these losses and credit carryforwards. The valuation allowance for 2018 is primarily the result of foreign losses due to the Company’s global re-organization of its foreign entities and these generally have no expiration date. Valuation allowances are also maintained with respect to deferred tax assets for certain federal and state carryforwards that may not be realized and that principally expire in 2038 . Tax Rate Reconciliation A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2018 2017 2016 Federal statutory tax rate 24.5 % 35.0 % 35.0 % New U.S. tax legislation (see discussion above) 54.6 — — State and local income taxes, net of federal tax benefit 0.8 (2.6 ) 1.5 Effect of foreign and Puerto Rico earnings and foreign tax credits 7.3 (40.8 ) (23.7 ) Effect of Research Credits and Domestic Production Activities (2.8 ) (2.7 ) (4.4 ) Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2) (6.7 ) (7.9 ) — Effect of gain on divestitures 1.3 — — Effect of uncertain tax position 3.3 — — Effect of valuation allowance release (4.8 ) — — Effect of application for change in accounting method (4.5 ) — — Effect of nondeductible compensation 1.6 — — Other, net (1.1 ) 6.3 0.7 Effective income tax rate 73.5 % (12.7 )% 9.1 % Tax Holidays and Payments The approximate amounts of tax reductions related to tax holidays in various countries in which the Company does business were $101 million , $144 million and $121 million , in 2018 , 2017 and 2016 , respectively. The benefit of the tax holiday on diluted earnings per share was approximately $0.38 , $0.64 and $0.56 for fiscal years 2018 , 2017 and 2016 , respectively. The tax holidays expire at various dates through 2028. The Company made income tax payments, net of refunds, of $235 million in 2018 , $265 million in 2017 and $218 million in 2016 .

Sale-Type Leases and Financing

Sale-Type Leases and Financing Receivables	12 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Sale-Type Leases and Financing Receivable	Sales-Type Leases and Financing Receivables In April 2017, in conjunction with the implementation of a new “go-to-market” business model for the Company's U.S. dispensing business within the Medication Management Solutions (“MMS”) unit of the Medical segment, the Company amended the terms of certain customer leases for dispensing equipment within the MMS unit. The modification provided customers the ability to reduce its dispensing asset base via a return provision, resulting in a more flexible lease term. Prior to the modification, these leases were accounted for as sales-type leases in accordance with Accounting Standards Codification Topic 840, "Leases", as the non-cancellable lease term of 5 years exceeded 75% of the equipment’s estimated useful life and the present value of the minimum lease payments exceeded 90% of the equipment’s fair value. As a result of the lease modification, the Company was required to reassess the classification of the leases due to the amended lease term. Accordingly, most amended lease contracts were classified as operating leases beginning in April 2017. The change in lease classification resulted in a pre-tax charge to earnings in fiscal year 2017 of $748 million , which was recorded in Other operating expense, net. Beginning April 1, 2017, revenue associated with these modified contracts has been recognized on a straight-line basis over the remaining lease term, along with depreciation on the reinstated leased assets. The Company's consolidated financial results in 2018 and 2017 were not materially impacted by the financing receivables remaining subsequent to the lease modification discussed above.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Other Income (Expense), Net (Millions of dollars) 2018 2017 2016 Losses on debt extinguishment (a) $ (16 ) $ (73 ) $ — Vyaire Medical-related amounts (b) 288 (3 ) — Other equity investment income 8 3 8 Losses on undesignated foreign exchange derivatives, net (14 ) (11 ) (3 ) Royalty income (c) 51 — — Gains on previously held investments (d) — 24 — Other — 3 7 Other income (expense), net $ 318 $ (57 ) $ 11 (a) Represents losses recognized upon our repurchase and extinguishment of certain senior notes, as further discussed in Note 15 . (b) Represents amounts related to the Company’s 2017 divestiture of a controlling interest in its former Respiratory Solutions business and the subsequent sale in 2018 of the remaining ownership interest. The amount in 2018 includes the gain on the sale of the remaining non-controlling interest and transition services agreement income, net of the Company's share of equity investee results. The amount in 2017 represents the Company’s share of equity investee results, net of transition services agreement income. Additional disclosures regarding these divestiture transactions are provided in Note 10 in the Notes to Consolidated Financial Statements. (c) Represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues. (d) Represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the Company acquired. Trade Receivables, Net The amounts recognized in 2018 , 2017 and 2016 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2015 $ 53 $ 9 $ 62 Additions charged to costs and expenses 23 37 60 Deductions and other (14 ) (a) (40 ) (55 ) Balance at September 30, 2016 $ 61 $ 6 $ 67 Additions charged to costs and expenses 25 43 68 Deductions and other (32 ) (a) (45 ) (76 ) Balance at September 30, 2017 $ 54 $ 4 $ 58 Additions charged to costs and expenses 31 58 89 Deductions and other (11 ) (a) (50 ) (61 ) Balance at September 30, 2018 $ 75 $ 12 $ 86 (a) Accounts written off. Inventories Inventories at September 30 consisted of: (Millions of dollars) 2018 2017 Materials $ 510 $ 313 Work in process 297 271 Finished products 1,644 1,234 $ 2,451 $ 1,818 The Company acquired $974 million of inventories in the Bard transaction which is further discussed in Note 9. Property, Plant and Equipment, Net Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2018 2017 Land $ 173 $ 146 Buildings 2,724 2,496 Machinery, equipment and fixtures 7,405 6,584 Leasehold improvements 182 163 10,485 9,389 Less accumulated depreciation and amortization 5,111 4,752 $ 5,375 $ 4,638 The Company acquired $553 million of property, plant and equipment assets, which largely consisted of machinery, equipment and fixtures, in the Bard transaction.

Supplementary Data (Unaudited)

Supplementary Data (Unaudited)	12 Months Ended
	Sep. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Supplemental Financial Data (Unaudited)	SUPPLEMENTARY QUARTERLY DATA (UNAUDITED) Millions of dollars, except per share amounts 2018 1 st 2 nd 3 rd 4 th Year Revenues $ 3,080 $ 4,222 $ 4,278 $ 4,402 $ 15,983 Gross Profit 1,550 1,604 2,017 2,091 7,262 Net (Loss) Income (136 ) (12 ) 594 (135 ) 311 (Loss) earnings per Share: (a) Basic (0.76 ) (0.19 ) 2.08 (0.64 ) 0.62 Diluted (0.76 ) (0.19 ) 2.03 (0.64 ) 0.60 2017 1 st 2 nd 3 rd 4 th Year Revenues $ 2,922 $ 2,969 $ 3,035 $ 3,166 $ 12,093 Gross Profit 1,452 1,432 1,504 1,554 5,942 Net Income (Loss) 562 344 (132 ) 327 1,100 Earnings (loss) per Share: (a) Basic 2.64 1.61 (0.75 ) 1.27 4.70 Diluted 2.58 1.58 (0.75 ) 1.24 4.60 (a) Earnings per share amounts are calculated from the underlying whole-dollar amounts. The sums of basic and diluted earnings per share for the quarters of 2018 and 2017 do not equal year-to-date amounts due to the impacts of shares issued during these fiscal years, in connection with the Bard acquisition, on the weighted average common shares included in the calculations of basic and diluted earnings per share. Additional disclosures regarding shares issued related to the Bard acquisition are provided in Notes 3 and 9.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities.
Cash Equivalents	Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Restricted Cash	Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard") which is further discussed in Note 9.
Short-Term Investments	Short-Term Investments Short-term investments consist of time deposits with maturities greater than three months and less than one year when purchased.
Trade and Financing Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible.
Inventories	Inventories Inventories are stated at the lower of first-in, first-out cost or market.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four to 13 years for machinery and equipment and one to 20 years for leasehold improvements.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill and in-process research and development assets which arise from acquisitions. The Company currently reviews all indefinite-lived assets, including goodwill, for impairment generally using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. Potential impairment of goodwill is generally identified by comparing the fair value of a reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2018 indicated that all identified reporting units’ fair values exceeded their respective carrying values. The review for impairment of in-process research and development assets is performed by comparing the fair value of the technology or project assets, estimated using an income approach, with their carrying value. In-process research and development assets are considered indefinite-lived assets and are reviewed at least annually for impairment until projects are completed or abandoned. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one to 40 years, using the straight-line method. Finite-lived intangible assets, including developed technology assets, are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value.
Foreign Currency Translation	Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss).
Revenue Recognition	Revenue Recognition Revenue from product sales is typically recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; product price is fixed or determinable; collection of the resulting receivable is reasonably assured. Certain sales arrangements contain multiple deliverables, including equipment and service deliverables, which requires the Company to determine the separate units of account. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price. Revenue allocated to certain equipment deliverables is recognized upon customer acceptance, which occurs after the transfer of title and risk of loss to the customer and the completion of installation or training services. When related services are considered inconsequential, delivery is deemed to occur upon the transfer of title and risk of loss, at which time revenue and the costs associated with services are recognized. For equipment lease revenue, transactions are evaluated and classified as either operating leases or sales-type leases. Generally, the Company's lease arrangements with customers are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period, as defined within the customer agreement. For products sold and leased with embedded software, if software is considered not essential to the non-software elements of a product but is considered more than incidental to a product as a whole, the product’s software elements must be separated from its non-software elements under the requirements relating to multiple-element arrangements and accounted for under software industry-specific revenue recognition requirements. However, if it is determined that the embedded software is more than incidental to the product as a whole but the non-software elements and software elements work together to deliver the essential functionality of the products as a whole, then the accounting for such product does not fall within the scope of software industry-specific accounting requirements. The Company’s domestic businesses sell products primarily to distributors that resell the products to end-user customers. Rebates are provided to distributors that sell to end-user customers at prices determined under a contract between the Company and the end-user customer. Provisions for rebates, as well as sales discounts and returns, are based upon estimates and are accounted for as a reduction of revenues when revenue is recognized.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are included in Selling and administrative expense .
Derivative Financial Instruments	Derivative Financial Instruments All derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized.
Income Taxes	Income Taxes The Company has historically asserted indefinite reinvestment of the earnings of certain non-U.S. subsidiaries outside the United States. New U.S. tax legislation, which is further discussed in Note 16, eliminated certain material tax effects on the repatriation of cash to the United States. Future repatriation of cash and other property held by the Company's foreign subsidiaries will generally not be subject to U.S. federal income tax. As a result, after reevaluation of the permanent reinvestment assertion, the Company is no longer permanently reinvested with respect to its historic unremitted foreign earnings as of September 30, 2018. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions, based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
Earnings per Share	Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.
New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted	New Accounting Principle Adopted In the second quarter of its fiscal year 2018, the Company prospectively adopted an accounting standard update issued by the Financial Accounting Standards Board ("FASB") relating to the stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 16. Additional disclosures regarding this accounting standard adoption are provided in Note 3. On October 1, 2016, the Company prospectively adopted amended requirements issued by the FASB relating to the timing of recognition and classification of share-based compensation award-related income tax effects. Upon adoption of the requirements in 2017, the Company has recorded tax benefits relating to share-based compensation awards within Income tax (benefit) provision on its consolidated statement of income. These tax benefits had been previously recorded within Capital in excess of par value on the Company's consolidated balance sheet. Also upon adoption of the amended guidance in 2017, the Company has classified excess tax benefits on its consolidated statement of cash flows within Net Cash Provided by Operating Activities , rather than Net Cash Provided by (Used for) Financing Activities . New Accounting Principles Not Yet Adopted In March 2017, the FASB issued an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. The Company's adoption of the new requirements on October 1, 2018 is not expected to have a material impact on its consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet. The new standard also requires expanded disclosures regarding leasing arrangements. The Company will adopt the standard on October 1, 2019 and has commenced its initial assessment of the impact on its consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard. Under this standard, revenue is recognized upon the transfer of goods or services to customers and the amount of revenue recognized reflects the consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on October 1, 2018 using the modified retrospective method. The Company assessed the impact that this new revenue recognition standard will have on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. The Company is currently finalizing the changes to its processes, systems and controls which are necessary to support recognition and disclosure under the new revenue recognition standard. The Company does not expect its adoption of the new standard to have a material impact on its consolidated financial statements.
Contingencies	Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. generally accepted accounting principles, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the investigative subpoena issued by the Department of Defense Inspector General and the Department of Health and Human Services and the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters As is further discussed in Note 9 , the Company completed its acquisition of Bard on December 29, 2017 and the following matters include Bard-related legal proceedings and claims that the Company assumed on the acquisition date (“Bard-related Product Liability Matters”). The Company believes that certain settlements and judgments, as well as some legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Hernia Product Claims As of September 30, 2018 , the Company is defending approximately 3,154 product liability claims involving Bard’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2019 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2018 , the Company is defending approximately 1,322 product liability claims involving Bard’s line of pelvic mesh devices. The majority of those claims are currently pending in a federal MDL in the United States District Court for the Southern District of West Virginia, but claims are also pending in other state and/or federal court jurisdictions, including a coordinated proceeding in New Jersey State Court. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,037 filed and unfiled claims that have been asserted or threatened against Bard but lack sufficient information to determine whether a Bard pelvic mesh device is actually at issue. The claims identified above also include products manufactured by both Bard and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of Bard. Medtronic has an obligation to defend and indemnify Bard with respect to any product defect liability relating to products its subsidiaries had manufactured. As described below, in July 2015 the Company reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects of Medtronic’s indemnification obligation. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of September 30, 2018 , the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,021 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated in 2018 and throughout 2019 in state courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ( $33 million compensatory; $35 million punitive). The Company is in the process of challenging that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months. In July 2015, as part of the agreement with Medtronic noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by Bard under supply agreements with Medtronic, and Bard has paid Medtronic $121 million towards these potential settlements. In June 2017, Bard amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. Bard also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between Bard and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of September 30, 2018 , the Company is defending approximately 4,515 product liability claims involving Bard’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but claims are also pending in other state and/or federal court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Trials are scheduled throughout 2018 in the MDL and state courts. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. In January 2017, the Company reached an agreement to resolve litigation filed in the Southern District of New York by its insurance carriers in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage. Other Legal Matters In June 2007, Retractable Technologies, Inc. (“RTI”) filed a complaint against the Company under the caption Retractable Technologies, Inc. vs. Becton Dickinson and Company (Civil Action No. 2:07-cv-250, U.S. District Court, Eastern District of Texas) alleging that the BD Integra™ syringes infringe patents licensed exclusively to RTI. Included in its complaint, RTI also alleged that the Company engaged in false advertising with respect to certain of the Company’s safety-engineered products in violation of the Lanham Act; acted to exclude RTI from various product markets and to maintain its market share through, among other things, exclusionary contracts in violation of state and federal antitrust laws; and engaged in unfair competition. In January 2008, the Court severed the patent and non-patent claims into separate cases. BD paid a $5 million award following an adverse infringement verdict at the district court and the Company's unsuccessful appeal. On September 19, 2013, a jury returned a verdict against BD with respect to RTI’s Lanham Act claim and claim for attempted monopolization based on deception in the safety syringe market. The jury awarded RTI $113.5 million for its attempted monopolization claim (which would be trebled under the antitrust statute). Upon issuance of a Court of Appeals decision reversing the attempted monopolization claim, the Company recorded a $337 million reversal of reserves associated with the initial judgment, in Other operating (income) expense, net , in the first quarter of fiscal year 2017. The Court of Appeals affirmed the judgment for Lanham Act liability, and remanded the case to the district court to consider whether and if so how much profit should be disgorged by BD on that claim. The Court of Appeals also vacated and remanded the injunction ordered by the district court. On January 31, 2017, RTI filed a petition for a writ of certiorari with the U.S. Supreme Court. On March 20, 2017, the U.S. Supreme Court denied certiorari, and the district court thereafter heard RTI’s request for disgorgement. On August 17, 2017, the district court entered judgment in favor of BD and ruled that RTI is not entitled to any award of money damages. RTI has appealed this ruling to the Fifth Circuit Court of Appeals. Oral argument on the appeal occurred on October 3, 2018. Since early 2013, Bard has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In November 2015, the Department of Defense Inspector General issued an investigative subpoena to Bard. The Department of Health and Human Services is also participating in this investigation. The subpoena seeks documents related to the Company’s sales and marketing of certain filter products, drug coated balloon catheters, and peripheral arterial disease detection products. In July 2017, a separate civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec ® and QuantaFlo TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Reserves Accruals for the Bard product liability claims which are specifically discussed above, as well as the related legal defense costs, amounted to approximately $2.0 billion at September 30, 2018 . Such amounts include provisional estimates which have been recorded with respect to the acquired liabilities. These amounts may be adjusted upon the availability of new or additional information regarding facts or circumstances which existed at the acquisition date. As of September 30, 2018 , the Company has $94 million in Bard-related qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash . The Company's expected recoveries related to Bard-related product liability claims and related legal defense costs were approximately $343 million at September 30, 2018 . A substantial amount of these expected recoveries at September 30, 2018 relate to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The terms of the Company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the Company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2018 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.
Fair Value of Financial Instruments	Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Changes in Certain Components of Shareholders' Equity	Changes in certain components of shareholders’ equity were as follows: Common Stock Issued at Par Value Capital in Excess of Par Value Retained Earnings Deferred Compensation Treasury Stock (Millions of dollars) Shares (in thousands) Amount Balance at September 30, 2015 $ 333 $ 4,475 $ 12,314 $ 20 (121,967 ) $ (8,239 ) Net income — — 976 — — — Cash dividends: Common ($2.64 per share) — — (562 ) — — — Common stock issued for: Share-based compensation and other plans, net — 27 (1 ) 2 2,607 26 Share-based compensation — 191 — — — — Common stock held in trusts, net (a) — — — — (11 ) — Balance at September 30, 2016 $ 333 $ 4,693 $ 12,727 $ 22 (119,371 ) $ (8,212 ) Net income — — 1,100 — — — Cash dividends: Common ($2.92 per share) — — (645 ) — — — Preferred — — (70 ) — — — Common stock issued for: Public equity offerings (b) 14 4,810 — — — — Share-based compensation and other plans, net — (65 ) (1 ) (3 ) 1,908 6 Share-based compensation — 180 — — — — Common stock held in trusts, net (a) — — — — 7 — Repurchase of common stock (c) — — — — (1,289 ) (220 ) Balance at September 30, 2017 $ 347 $ 9,619 $ 13,111 $ 19 (118,745 ) $ (8,427 ) Net income — — 311 — — — Cash dividends: Common ($3.00 per share) — — (775 ) — — — Preferred — — (152 ) — — — Common stock issued for: Acquisition (see Note 9) — 6,478 — — 37,306 2,121 Share-based compensation and other plans, net — (246 ) (2 ) 3 2,982 62 Share-based compensation — 328 — — — — Common stock held in trusts, net (a) — — — — (6 ) — Effect of change in accounting principle (see Note 2 and further discussion below) — — 103 — — — Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463 ) $ (6,243 ) (a) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) In May 2017 and in connection with the Company's acquisition of Bard, which is further discussed in Note 9 , the Company completed registered public offerings of equity securities including 14.025 million shares of the Company's common stock and 2.475 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for total net proceeds of $4.8 billion . If and when declared, dividends on the mandatory convertible preferred stock are payable on a cumulative basis at an annual rate of 6.125% on the liquidation preference of $1,000 per preferred share ( $50 per depositary share). The shares of preferred stock are convertible to a minimum of 11.7 million and up to a maximum of 14.0 million shares of Company common stock at an exchange ratio that is based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of May 1, 2020. (c) Using proceeds received from the divestiture of the Respiratory Solutions business in the first quarter of fiscal year 2017, the Company repurchased shares of its common stock under an accelerated share repurchase agreement.
Accumulated Other Comprehensive (Loss) Income	The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Currency Translation Benefit Plans Cash Flow Hedges Balance at September 30, 2015 $ (1,738 ) $ (961 ) $ (741 ) $ (36 ) Other comprehensive loss before reclassifications, net of taxes (251 ) (50 ) (190 ) (11 ) Amounts reclassified into income, net of 60 — 48 12 Balance at September 30, 2016 $ (1,929 ) $ (1,011 ) $ (883 ) $ (35 ) Other comprehensive income before reclassifications, net of taxes 140 11 121 8 Amounts reclassified into income, net of 66 — 58 8 Balance at September 30, 2017 $ (1,723 ) $ (1,001 ) $ (703 ) $ (18 ) Other comprehensive (loss) income before reclassifications, net of taxes (142 ) (161 ) 19 — Amounts reclassified into income, net of taxes 57 — 52 5 Tax effects reclassified to retained earnings (103 ) — (99 ) (4 ) Balance at September 30, 2018 $ (1,909 ) $ (1,162 ) $ (729 ) $ (17 )
Other Comprehensive Income (Loss), Tax	The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2018 2017 2016 Benefit Plans Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income $ (19 ) $ (60 ) $ 79

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share	The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2018 2017 2016 Average common shares outstanding 258,354 218,943 212,702 Dilutive share equivalents from share-based plans (a) (b) 6,267 4,645 4,834 Average common and common equivalent shares outstanding — assuming dilution 264,621 223,588 217,536 (a) For the years ended September 30, 2018 and 2017 , dilutive share equivalents associated with mandatory convertible preferred stock of 12 million and 5 million , respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3 . For the years ended September 30, 2018 , 2017 and 2016 , there were no options to purchase shares of common stock which were excluded from the diluted earnings per share calculation. (b) The adjustment to calculate diluted share equivalents from share-based plans in 2016 included excess tax benefits relating to share-based compensation awards. Upon the Company's adoption, as discussed in Note 2 , of new accounting requirements relating to share-based compensation award-related income tax effects, the adjustments in 2018 and 2017 excluded these excess tax benefits.

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Financial Information for Company's Segments	(Millions of dollars) 2018 2017 2016 Revenues (a) Medical (b) $ 8,616 $ 7,419 $ 7,965 Life Sciences 4,330 3,988 3,829 Interventional (b) 3,037 685 689 Total Revenues $ 15,983 $ 12,093 $ 12,483 Income Before Income Taxes Medical (b) (c) (d) $ 2,624 $ 1,907 $ 1,807 Life Sciences (e) 1,207 772 793 Interventional (b) (c) 306 248 245 Total Segment Operating Income 4,137 2,927 2,845 Acquisitions and other restructurings (744 ) (354 ) (728 ) Net interest expense (641 ) (445 ) (367 ) Other unallocated items (f) (1,578 ) (1,152 ) (676 ) Total Income Before Income Taxes $ 1,173 $ 976 $ 1,074 Assets Medical (b) $ 23,493 $ 15,552 $ 16,370 Life Sciences 4,225 4,056 3,848 Interventional (b) 23,219 2,780 2,784 Total Segment Assets 50,938 22,388 23,002 Corporate and All Other (g) 2,966 15,347 2,584 Total Assets $ 53,904 $ 37,734 $ 25,586 Capital Expenditures Medical (b) $ 560 $ 486 $ 464 Life Sciences 255 212 200 Interventional (b) 65 16 18 Corporate and All Other 14 13 12 Total Capital Expenditures $ 895 $ 727 $ 693 Depreciation and Amortization Medical (b) $ 1,028 $ 773 $ 801 Life Sciences 275 254 254 Interventional (b) 658 52 56 Corporate and All Other 17 10 3 Total Depreciation and Amortization $ 1,978 $ 1,088 $ 1,114 (a) The Company has no material intersegment revenues. (b) Prior-year amounts have been reclassified to reflect the movement of certain product offerings previously reported in the Medical segment and which are now reported in the Interventional segment, as further discussed above. Accordingly, all amounts presented in 2017 and 2016 for the Interventional segment are associated with these products. (c) The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million , respectively. (d) The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. (e) The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit. (f) The amounts in 2018 , 2017 and 2016 comprised of foreign exchange, corporate expenses, and share-based compensation expense. Results in 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves as further discussed in Note 5 . (g) Includes cash and investments and corporate assets.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment	Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2018 2017 2016 Revenues United States $ 8,768 $ 6,504 $ 6,893 Europe 3,298 2,588 2,674 Greater Asia 2,460 1,744 1,692 Other 1,457 1,257 1,225 $ 15,983 $ 12,093 $ 12,483 Long-Lived Assets United States $ 38,982 $ 13,151 $ 14,075 Europe 5,640 4,421 3,747 Greater Asia 851 578 586 Other 645 584 483 Corporate 375 366 329 $ 46,494 $ 19,101 $ 19,220

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Cost Relating to Share-Based Payments	The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2018 2017 2016 Cost of products sold $ 36 $ 30 $ 29 Selling and administrative expense 136 113 106 Research and development expense 29 24 22 Acquisitions and other restructurings 130 10 39 $ 332 $ 177 $ 196 Tax benefit associated with share-based compensation costs recognized $ 79 $ 61 $ 69
Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods	The fair value was estimated on the date of grant using a lattice-based binomial option valuation model that uses the following weighted-average assumptions: 2018 2017 2016 Risk-free interest rate 2.32% 2.33% 2.17% Expected volatility 19.0% 20.0% 19.0% Expected dividend yield 1.33% 1.71% 1.76% Expected life 7.4 years 7.5 years 7.6 years Fair value derived $46.10 $33.81 $27.69
Summary of SARs Outstanding	A summary of SARs outstanding as of September 30, 2018 and changes during the year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions of dollars) Balance at October 1 6,466 $ 117.94 Granted 4,295 123.97 Exercised (2,511 ) 98.67 Forfeited, canceled or expired (264 ) 163.69 Balance at September 30 7,986 $ 125.73 5.88 $ 1,080 Vested and expected to vest at September 30 7,732 $ 124.10 5.81 $ 1,059 Exercisable at September 30 5,450 $ 102.66 4.90 $ 863
Schedule Of Share Based Compensation, Summary of Stock Appreciation Rights Exercised [Table Text Block]	A summary of SARs exercised 2018 , 2017 and 2016 is as follows: (Millions of dollars) 2018 2017 2016 Total intrinsic value of SARs exercised $ 333 $ 148 $ 148 Tax benefit realized from SAR exercises $ 90 $ 53 $ 52 Total fair value of SARs vested $ 107 $ 30 $ 24
Summary of Performance-Based Restricted Stock Units Outstanding	A summary of restricted stock units outstanding as of September 30, 2018 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in thousands) Weighted Average Grant Date Fair Value Stock Units (in thousands) Weighted Average Grant Date Fair Value Balance at October 1 1,080 $ 161.64 2,136 $ 142.06 Granted 338 251.75 2,903 216.06 Distributed (119 ) 156.65 (1,368 ) 167.86 Forfeited or canceled (267 ) 173.67 (906 ) 178.87 Balance at September 30 1,032 (a) $ 190.57 2,765 $ 194.92 Expected to vest at September 30 548 (b) $ 192.35 2,585 $ 193.90 (a) Based on 200% of target payout. (b) Net of expected forfeited units and units in excess of the expected performance payout of 64 thousand and 420 thousand shares, respectively.
Schedule Of Share Based Compensation, Restricted Stock Units, Grant Date Fair Value of Units Granted [Table Text Block]	The weighted average grant date fair value of restricted stock units granted during the years 2018 , 2017 and 2016 are as follows: Performance-Based Time-Vested 2018 2017 2016 2018 2017 2016 Weighted average grant date fair value of units granted $ 251.75 $ 174.92 $ 153.73 $ 216.06 $ 165.96 $ 145.57
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	The total fair value of stock units vested during 2018 , 2017 and 2016 was as follows: Performance-Based Time-Vested (Millions of dollars) 2018 2017 2016 2018 2017 2016 Total fair value of units vested $ 31 $ 32 $ 22 $ 362 $ 139 $ 114

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Sep. 30, 2018
Net Pension and Other Postretirement Cost	Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2018 2017 2016 Service cost $ 136 $ 110 $ 81 Interest cost 90 61 72 Expected return on plan assets (154 ) (112 ) (109 ) Amortization of prior service credit (13 ) (14 ) (15 ) Amortization of loss 78 92 77 Settlements 2 — 7 Net pension cost $ 137 $ 138 $ 113 Net pension cost included in the preceding table that is attributable to international plans $ 34 $ 43 $ 35
Change in Benefit Obligation, Change in Fair Value of Plan Assets	The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2018 2017 Change in benefit obligation: Beginning obligation $ 2,647 $ 2,719 Service cost 136 110 Interest cost 90 61 Plan amendments — (1 ) Benefits paid (162 ) (123 ) Impact of acquisitions (divestitures) 758 (19 ) Actuarial gain (82 ) (134 ) Settlements (122 ) (1 ) Other, includes translation (19 ) 36 Benefit obligation at September 30 $ 3,246 $ 2,647 Change in fair value of plan assets: Beginning fair value $ 1,932 $ 1,855 Actual return on plan assets 70 134 Employer contribution 400 54 Benefits paid (162 ) (123 ) Impact of acquisitions (divestitures) 539 (13 ) Settlements (122 ) (1 ) Other, includes translation (15 ) 26 Plan assets at September 30 $ 2,642 $ 1,932 Funded Status at September 30: Unfunded benefit obligation $ (604 ) $ (715 ) Amounts recognized in the Consolidated Balance Sheets at September 30: Other $ 15 $ 9 Salaries, wages and related items (15 ) (17 ) Long-term Employee Benefit Obligations (604 ) (707 ) Net amount recognized $ (604 ) $ (715 ) Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30: Prior service credit $ 60 $ 74 Net actuarial loss (982 ) (1,065 ) Net amount recognized $ (921 ) $ (991 )
Pension Plans with Accumulated Benefit Obligations	Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Obligation Exceeds the Fair Value of Plan Assets Projected Benefit Obligation Exceeds the Fair Value of Plan Assets (Millions of dollars) 2018 2017 2018 2017 Projected benefit obligation $ 2,618 $ 2,551 $ 3,121 $ 2,613 Accumulated benefit obligation $ 2,533 $ 2,470 Fair value of plan assets $ 2,012 $ 1,833 $ 2,502 $ 1,889
Weighted Average Assumptions Determining Pension Plan	The weighted average assumptions used in determining pension plan information were as follows: 2018 2017 2016 Net Cost Discount rate: U.S. plans (a) 3.71 % 3.42 % 4.15 % International plans 2.30 1.70 2.84 Expected return on plan assets: U.S. plans 7.20 7.25 7.50 International plans 4.95 4.65 5.02 Rate of compensation increase: U.S. plans 4.51 4.25 4.25 International plans 2.31 2.33 2.33 Benefit Obligation Discount rate: U.S. plans 4.26 3.72 3.42 International plans 2.30 2.25 1.70 Rate of compensation increase: U.S. plans 4.29 4.51 4.25 International plans 2.36 2.30 2.33 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period.
Expected Benefit Payments	Expected benefit payments are as follows: (Millions of dollars) Pension Plans Other Postretirement Benefits 2019 $ 213 $ 14 2020 202 14 2021 208 13 2022 209 13 2023 214 12 2024-2028 1,096 54
Fair Value Measurements of U.S. Plan Assets	The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2018 and 2017 . The categorization of fund investments is based upon the categorization of these funds’ underlying assets. (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Fixed Income: Mortgage and asset-backed securities $ 28 $ 155 $ — $ — $ — $ — $ 28 $ 155 $ — $ — Corporate bonds 484 232 — — 101 89 383 144 — — Government and agency-U.S. 257 107 — — 199 83 57 25 — — Government and agency-Foreign 122 98 8 12 85 63 28 22 — — Equity securities 536 369 360 307 176 62 — — — — Cash and cash equivalents 39 40 — — 39 40 — — — — Other 356 252 356 217 — 34 — — — — Fair value of plan assets $ 1,821 $ 1,254 $ 724 $ 537 $ 600 $ 371 $ 497 $ 346 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator.
Fair Value Measurements of Foreign Plan Assets	The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2018 and 2017 . (Millions of dollars) Total International Plan Asset Balances Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Significant Unobservable Inputs (Level 3) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Fixed Income: Corporate bonds $ 28 $ 14 $ — $ — $ 14 $ — $ 14 $ 13 $ — $ — Government and agency-U.S. 6 5 — — 3 1 3 3 — — Government and agency-Foreign 150 127 — — 104 83 46 45 — — Other fixed income 96 64 — — 63 57 33 7 — — Equity securities 314 256 15 13 299 242 — — — — Cash and cash equivalents 9 28 — — 9 28 — — — — Real estate 30 26 — — — — 30 26 — — Insurance contracts 114 98 — — — — — — 114 98 Other 74 62 — — 55 47 20 15 — — Fair value of plan assets $ 821 $ 678 $ 15 $ 13 $ 546 $ 459 $ 146 $ 108 $ 114 $ 98 (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator.
Pension Plans | Foreign Plans
Changes in Fair Value Pension Assets Measured Using Level 3 Inputs	The following table summarizes the changes, for the years ended September 30, 2018 and 2017 , in the fair value of international pension assets measured using Level 3 inputs: (Millions of dollars) Insurance Contracts Balance at September 30, 2016 $ 102 Actual return on plan assets: Relating to assets held at September 30, 2016 1 Purchases, sales and settlements, net (11 ) Transfers in from other categories 1 Exchange rate changes 4 Balance at September 30, 2017 $ 98 Actual return on plan assets: Relating to assets held at September 30, 2017 2 Purchases, sales and settlements, net 15 Transfers in from other categories 1 Exchange rate changes (2 ) Balance at September 30, 2018 $ 114

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Schedule Of Business Acquisition By Acquisition Fair Value Of Consideration Transferred Table	The acquisition-date fair value of consideration transferred consisted of the components below. The fair value of the shares and equity awards issued as consideration was recognized as a $6.5 billion increase to Capital in excess of par value and a $2.1 billion decrease to Common stock in treasury. (Millions of dollars) Cash consideration $ 16,400 Non-cash consideration-fair value of shares issued 8,004 Non-cash consideration-fair value of equity awards issued 613 Total consideration transferred $ 25,017
Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable	The acquisition-date fair value of the Company’s ordinary shares issued to Bard shareholders was calculated per the following (shares in millions): (Millions of dollars, except per share data) Total Bard shares outstanding 73.359 Conversion factor 0.5077 Conversion of Bard shares outstanding 37.243 Conversion of pre-acquisition equity awards 0.104 Total number of the Company's share issued 37.347 Closing price of the Company’s stock $ 214.32 Fair value of the Company’s issued shares $ 8,004
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary allocations of the purchase price below provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates will be adjusted upon the availability of further information regarding events or circumstances which existed at the acquisition date and such adjustments may be significant. The assets acquired and liabilities assumed in this acquisition, as recorded in the Company's consolidated balance sheet at September 30, 2018 , were largely allocated to the Company's new Interventional segment. (Millions of dollars) Cash and equivalents $ 1,480 Trade receivables 472 Inventories 974 Property, plant and equipment 553 Developed technology 10,469 Customer relationships 1,146 Other assets 624 Total identifiable assets acquired 15,718 Payables, accrued expenses and other liabilities 1,276 Short term and long-term debt 1,692 Product liability and other legal reserves 2,029 Deferred tax liabilities 1,713 Total liabilities assumed 6,711 Net identifiable assets acquired 9,007 Goodwill 16,009 Net assets acquired $ 25,017
Business Acquisition, Pro Forma Information	The following table provides the pro forma results for the fiscal years 2018 and 2017 as if Bard had been acquired as of October 1, 2016. (Millions of dollars, except per share data) 2018 2017 Revenues $ 16,947 $ 15,781 Net Income $ 390 $ 1,145 Diluted Earnings per Share $ 0.90 $ 3.60

Business Restructuring Charges

Business Restructuring Charges Business Restructuring Charges (Tables)	12 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Summary of Restructuring Accrual Activity	Restructuring liability activity in 2018 , 2017 and 2016 was as follows: Employee Termination Other Total (Millions of dollars) Bard CareFusion/Other Initiatives (a) Bard (b) CareFusion/Other Initiatives (c) Bard CareFusion/Other Initiatives Balance at September 30, 2015 $ — $ 62 $ — $ — $ — $ 62 Charged to expense — 81 — 445 — 526 Cash payments — (76 ) — (72 ) — (148 ) Non-cash settlements — — — (39 ) — (39 ) Other adjustments — — — (332 ) — (332 ) Balance at September 30, 2016 $ — $ 67 $ — $ 2 $ — $ 69 Charged to expense — 27 — 58 — 85 Cash payments — (45 ) — (12 ) — (57 ) Non-cash settlements — — — (9 ) — (9 ) Other adjustments — — — (33 ) — (33 ) Balance at September 30, 2017 $ — $ 49 $ — $ 6 $ — $ 55 Charged to expense 136 30 156 22 292 52 Cash payments (103 ) (56 ) (3 ) (23 ) (106 ) (79 ) Non-cash settlements — — (153 ) (1 ) (153 ) (1 ) Other adjustments — — — — — — Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 (a) Expenses in fiscal year 2016 included $40 million relating to the CareFusion acquisition as well as $13 million for employee termination costs resulting from the Company's transition of certain elements of its information technology function to an outsourced model as further disclosed below. (b) Expenses in 2018 represented the cost associated with the conversion of certain pre-acquisition equity awards of Bard to BD equity awards as well as costs relating to Bard’s pension plan, partially offset by a gain on the sale of the Company's soft tissue core needle biopsy product line which was recorded in the second quarter of fiscal year 2018. (c) Expenses in 2016 included $214 million non-cash charge to recognize the impairment of capitalized internal-use software assets held for sale upon the Company’s decision to transition certain business information systems assets to a third party. Expenses in 2016 also included non-cash impairment charges of $81 million , after-tax, relating to the Company's disposition of certain non-core businesses, including the Company's sale of a majority interest in its Respiratory Solutions business during the first quarter of fiscal year 2017, which is further discussed in Note 10 .

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	Intangible assets at September 30 consisted of: 2018 2017 (Millions of dollars) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets Developed technology $ 13,966 $ 1,782 $ 3,508 $ 1,029 Customer relationships 4,584 861 3,393 564 Product rights 121 58 131 54 Trademarks 407 84 408 65 Patents and other 397 288 370 274 Amortized intangible assets $ 19,475 $ 3,073 $ 7,811 $ 1,986 Unamortized intangible assets Acquired in-process research and development $ 37 $ 67 Trademarks 2 2 Unamortized intangible assets $ 39 $ 69
Reconciliation of Goodwill by Business Segment	The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2016 $ 6,688 $ 731 $ — $ 7,419 Acquisitions (a) 119 24 — 143 Divestiture (b) (25 ) — — (25 ) Purchase accounting adjustments 4 — — 4 Currency translation 16 6 — 22 Goodwill as of September 30, 2017 $ 6,802 $ 761 $ — $ 7,563 Acquisitions (c) 3,923 76 11,218 15,217 Divestiture (b) — (59 ) (57 ) (116 ) Reallocation of goodwill for change in segment and reporting unit composition (d) (877 ) — 877 — Purchase accounting adjustments (e) 228 (2 ) 732 959 Currency translation (22 ) (2 ) — (24 ) Goodwill as of September 30, 2018 $ 10,054 $ 775 $ 12,771 $ 23,600 (a) Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (b) Represents goodwill derecognized upon the Company's sale of certain businesses, as further discussed in Note 10 . (c) Represents goodwill primarily recognized upon the Company's acquisition of Bard in fiscal year 2018, which is further discussed in Note 9 . Also includes goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (d) Represents the reassignment of goodwill, determined based upon a relative fair value allocation approach, associated with the movement of certain product offerings which were previously reported in the Medical segment and which are now reported in the Interventional segment as further discussed in Note 6 . (e) The purchase accounting adjustments increasing goodwill were primarily driven by the valuation of Bard developed technology assets, the associated deferred tax liability changes, increases to legal reserves and the alignment of the combined organization's accounting policies with respect to accrued liabilities and other accounts.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Summary of Short-Term Debt	Short-term debt at September 30 consisted of: (Millions of dollars) 2018 2017 Current portion of long-term debt 2.133% Notes due June 6, 2019 724 — 0.368% Notes due June 6, 2019 (a) 1,157 — 4.900% Notes due April 15, 2018 — 200 Term Loan Facility due September 5, 2019 (b) 710 — Other 10 3 Total short-term debt $ 2,601 $ 203 (a) Includes notes issued during fiscal year 2018, as further discussed below. (b) Term loan facility entered into during the fourth quarter of fiscal year 2018, as further discussed below.
Summary of Long-Term Debt	The aggregate principal amounts of Bard notes which were validly tendered for notes issued by the Company are provided below. (Millions of dollars) Interest Rate and Maturity Aggregate Principal Amount Principal Amount Accepted for Exchange 4.400% Notes due January 15, 2021 $ 500 $ 432 3.000% Notes due May 15, 2026 500 470 6.700% Notes due December 1, 2026 150 137 Total $ 1,150 $ 1,039 Long-Term Debt at September 30 consisted of: (Millions of dollars) 2018 2017 2.133% Notes due June 6, 2019 $ — $ 723 0.368% Notes due June 6, 2019 — 823 2.675% Notes due December 15, 2019 1,123 1,121 2.404% Notes due June 5, 2020 998 996 3.250% Notes due November 12, 2020 699 698 Floating Rate Notes due December 29, 2020 (a) 996 — 3.125% Notes due November 8, 2021 990 1,003 2.894% Notes due June 6, 2022 1,793 1,791 Floating Rate Notes due June 6, 2022 498 497 1.000% Notes due December 15, 2022 576 586 3.300% Notes due March 1, 2023 296 296 1.401% Notes due May 24, 2023 (a) 346 — 3.875% Notes due May 15, 2024 182 182 3.363% Notes due June 6, 2024 1,738 1,736 3.734% Notes due December 15, 2024 1,368 1,367 3.020% Notes due May 24, 2025 (a) 324 — 6.700% Notes due December 1, 2026 (b) 177 — 1.900% Notes due December 15, 2026 575 585 3.700% Notes due June 6, 2027 2,383 2,381 7.000% Debentures due August 1, 2027 156 166 6.700% Debentures due August 1, 2028 154 164 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 296 296 4.875% Notes due May 15, 2044 331 331 4.685% Notes due December 15, 2044 1,159 1,189 4.669% Notes due June 6, 2047 1,484 1,484 Other long-term debt 8 3 Total Long-Term Debt $ 18,894 $ 18,667 (a) Includes notes issued during fiscal year 2018, as further discussed below. (b) Includes notes assumed in connection with the Company's acquisition of Bard, as further discussed below.
Summary of Interest Costs and Payments	A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2018 2017 2016 Charged to operations $ 706 $ 521 $ 388 Capitalized 42 32 30 Total interest costs $ 748 $ 553 $ 418 Interest paid, net of amounts capitalized $ 674 $ 435 $ 392

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Provision for Income Taxes from Continuing Operations	The provision for income taxes the years ended September 30 consisted of: (Millions of dollars) 2018 2017 2016 Current: Federal $ 665 $ (230 ) $ 312 State and local, including Puerto Rico 73 (20 ) 17 Foreign 387 200 286 $ 1,124 $ (50 ) $ 616 Deferred: Domestic $ (201 ) $ (64 ) $ (441 ) Foreign (61 ) (10 ) (78 ) (262 ) (74 ) (519 ) Income tax provision (benefit) $ 862 $ (124 ) $ 97
Components of Income from Continuing Operations Before Income Taxes	The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2018 2017 2016 Domestic, including Puerto Rico $ (135 ) $ (386 ) $ (232 ) Foreign 1,308 1,362 1,306 Income Before Income Taxes $ 1,173 $ 976 $ 1,074
Summary of Gross Amounts of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that certain audits will close within the next twelve months but no significant increases or decreases in the amount of the unrecognized tax benefits are expected to result. (Millions of dollars) 2018 2017 2016 Balance at October 1 $ 349 $ 469 $ 593 Increase due to acquisitions 140 — — Increase due to current year tax positions 43 41 81 Increase due to prior year tax positions 43 19 10 Decreases due to prior year tax positions — (30 ) (3 ) Decrease due to settlements with tax authorities (29 ) (145 ) (147 ) Decrease due to lapse of statute of limitations (3 ) (5 ) (65 ) Balance at September 30 $ 543 $ 349 $ 469
Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2018 2017 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 458 $ — $ 618 $ — Property and equipment — 253 — 244 Intangibles — 2,948 — 1,584 Loss and credit carryforwards 1,290 — 1,098 — Other 707 384 531 164 2,455 3,585 2,247 1,992 Valuation allowance (1,181 ) — (1,032 ) — Net (a) $ 1,275 $ 3,585 $ 1,216 $ 1,992 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other on the consolidated balance sheets .
Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate	A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2018 2017 2016 Federal statutory tax rate 24.5 % 35.0 % 35.0 % New U.S. tax legislation (see discussion above) 54.6 — — State and local income taxes, net of federal tax benefit 0.8 (2.6 ) 1.5 Effect of foreign and Puerto Rico earnings and foreign tax credits 7.3 (40.8 ) (23.7 ) Effect of Research Credits and Domestic Production Activities (2.8 ) (2.7 ) (4.4 ) Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2) (6.7 ) (7.9 ) — Effect of gain on divestitures 1.3 — — Effect of uncertain tax position 3.3 — — Effect of valuation allowance release (4.8 ) — — Effect of application for change in accounting method (4.5 ) — — Effect of nondeductible compensation 1.6 — — Other, net (1.1 ) 6.3 0.7 Effective income tax rate 73.5 % (12.7 )% 9.1 %

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other Income (Expense), Net (Millions of dollars) 2018 2017 2016 Losses on debt extinguishment (a) $ (16 ) $ (73 ) $ — Vyaire Medical-related amounts (b) 288 (3 ) — Other equity investment income 8 3 8 Losses on undesignated foreign exchange derivatives, net (14 ) (11 ) (3 ) Royalty income (c) 51 — — Gains on previously held investments (d) — 24 — Other — 3 7 Other income (expense), net $ 318 $ (57 ) $ 11 (a) Represents losses recognized upon our repurchase and extinguishment of certain senior notes, as further discussed in Note 15 . (b) Represents amounts related to the Company’s 2017 divestiture of a controlling interest in its former Respiratory Solutions business and the subsequent sale in 2018 of the remaining ownership interest. The amount in 2018 includes the gain on the sale of the remaining non-controlling interest and transition services agreement income, net of the Company's share of equity investee results. The amount in 2017 represents the Company’s share of equity investee results, net of transition services agreement income. Additional disclosures regarding these divestiture transactions are provided in Note 10 in the Notes to Consolidated Financial Statements. (c) Represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues. (d) Represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the Company acquired.
Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts	The amounts recognized in 2018 , 2017 and 2016 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2015 $ 53 $ 9 $ 62 Additions charged to costs and expenses 23 37 60 Deductions and other (14 ) (a) (40 ) (55 ) Balance at September 30, 2016 $ 61 $ 6 $ 67 Additions charged to costs and expenses 25 43 68 Deductions and other (32 ) (a) (45 ) (76 ) Balance at September 30, 2017 $ 54 $ 4 $ 58 Additions charged to costs and expenses 31 58 89 Deductions and other (11 ) (a) (50 ) (61 ) Balance at September 30, 2018 $ 75 $ 12 $ 86 (a) Accounts written off.
Inventories	Inventories at September 30 consisted of: (Millions of dollars) 2018 2017 Materials $ 510 $ 313 Work in process 297 271 Finished products 1,644 1,234 $ 2,451 $ 1,818
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2018 2017 Land $ 173 $ 146 Buildings 2,724 2,496 Machinery, equipment and fixtures 7,405 6,584 Leasehold improvements 182 163 10,485 9,389 Less accumulated depreciation and amortization 5,111 4,752 $ 5,375 $ 4,638

Supplementary Data (Unaudited)

Supplementary Data (Unaudited) (Tables)	12 Months Ended
	Sep. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	SUPPLEMENTARY QUARTERLY DATA (UNAUDITED) Millions of dollars, except per share amounts 2018 1 st 2 nd 3 rd 4 th Year Revenues $ 3,080 $ 4,222 $ 4,278 $ 4,402 $ 15,983 Gross Profit 1,550 1,604 2,017 2,091 7,262 Net (Loss) Income (136 ) (12 ) 594 (135 ) 311 (Loss) earnings per Share: (a) Basic (0.76 ) (0.19 ) 2.08 (0.64 ) 0.62 Diluted (0.76 ) (0.19 ) 2.03 (0.64 ) 0.60 2017 1 st 2 nd 3 rd 4 th Year Revenues $ 2,922 $ 2,969 $ 3,035 $ 3,166 $ 12,093 Gross Profit 1,452 1,432 1,504 1,554 5,942 Net Income (Loss) 562 344 (132 ) 327 1,100 Earnings (loss) per Share: (a) Basic 2.64 1.61 (0.75 ) 1.27 4.70 Diluted 2.58 1.58 (0.75 ) 1.24 4.60 (a) Earnings per share amounts are calculated from the underlying whole-dollar amounts. The sums of basic and diluted earnings per share for the quarters of 2018 and 2017 do not equal year-to-date amounts due to the impacts of shares issued during these fiscal years, in connection with the Bard acquisition, on the weighted average common shares included in the calculations of basic and diluted earnings per share. Additional disclosures regarding shares issued related to the Bard acquisition are provided in Notes 3 and 9.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Summary of Significant Accounting Policies [Line Items]
Depreciation and amortization expense	$ 600	$ 406	$ 452
Selling and administrative expense	4,015	2,925	3,005
Shipping and Handling [Member]
Summary of Significant Accounting Policies [Line Items]
Selling and administrative expense	$ 479	$ 365	$ 401
Minimum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Minimum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Minimum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	10 years
Minimum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	1 year
Minimum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years
Minimum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	4 years
Minimum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	1 year
Maximum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Maximum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	20 years
Maximum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Maximum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	40 years
Maximum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	45 years
Maximum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	13 years
Maximum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years

Shareholders' Equity - Changes

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				$ 12,948					$ 12,948
Beginning balance (shares)				(118,744,758)					(118,744,758)
Net Income	$ (135)	$ 594	$ (12)	$ (136)	$ 327	$ (132)	$ 344	$ 562	$ 311	$ 1,100	$ 976
Ending balance	$ 20,994				$ 12,948				$ 20,994	$ 12,948
Ending balance (shares)	(78,462,971)				(118,744,758)				(78,462,971)	(118,744,758)
Common Stock Issued at Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				347				333	$ 347	$ 333	333
Stock Issued During Period, Value, New Issues										14
Ending balance	$ 347				$ 347				347	347	333
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				9,619				4,693	9,619	4,693	4,475
Stock Issued During Period, Value, Acquisitions									6,478
Stock Issued During Period, Value, New Issues										4,810
Share-based compensation and other plans, net									(246)	(65)	27
Share-based compensation									328	180	191
Ending balance	16,179				9,619				16,179	9,619	4,693
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				13,111				12,727	13,111	12,727	12,314
Net Income									311	1,100	976
Cash dividends, common									(775)	(645)	(562)
Dividends, Preferred Stock									(152)	(70)
Share-based compensation and other plans, net									(2)	(1)	(1)
Effect of change in accounting principle (see Note 2 and further discussion below)	103								103
Ending balance	12,596				13,111				12,596	13,111	12,727
Deferred Compensation
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				19				22	19	22	20
Share-based compensation and other plans, net									3	(3)	2
Ending balance	22				19				22	19	22
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				$ (8,427)				$ (8,212)	$ (8,427)	$ (8,212)	$ (8,239)
Beginning balance (shares)				(118,745,000)				(119,371,000)	(118,745,000)	(119,371,000)	(121,967,000)
Stock Issued During Period, Value, Acquisitions									$ 2,121
Stock Issued During Period, Shares, Acquisitions									37,306,000
Share-based compensation and other plans, net									$ 62	$ 6	$ 26
Share-based compensation plans, net (shares)									2,982,000	1,908,000	2,607,000
Common stock held in trusts, net (shares)									(6,000)	7,000	(11,000)
Repurchase of common stock (shares)										(1,289,000)
Repurchase of common stock										$ (220)
Ending balance	$ (6,243)				$ (8,427)				$ (6,243)	$ (8,427)	$ (8,212)
Ending balance (shares)	(78,463,000)				(118,745,000)				(78,463,000)	(118,745,000)	(119,371,000)

Shareholders' Equity - Change_2

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail II) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Common stock dividend per share (USD per share)	$ 3	$ 2.92	$ 2.64

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	$ (1,723)	$ (1,929)	$ (1,738)
Other comprehensive loss before reclassifications, net of taxes	(142)	140	(251)
Amounts reclassified into income, net of taxes	57	66	60
Tax effects reclassified to retained earnings	(103)
Accumulated other comprehensive (loss) income, ending balance	(1,909)	(1,723)	(1,929)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(1,001)	(1,011)	(961)
Other comprehensive loss before reclassifications, net of taxes	(161)	11	(50)
Amounts reclassified into income, net of taxes	0	0	0
Tax effects reclassified to retained earnings	0
Accumulated other comprehensive (loss) income, ending balance	(1,162)	(1,001)	(1,011)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(703)	(883)	(741)
Other comprehensive loss before reclassifications, net of taxes	19	121	(190)
Amounts reclassified into income, net of taxes	52	58	48
Tax effects reclassified to retained earnings	(99)
Accumulated other comprehensive (loss) income, ending balance	(729)	(703)	(883)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(18)	(35)	(36)
Other comprehensive loss before reclassifications, net of taxes	0	8	(11)
Amounts reclassified into income, net of taxes	5	8	12
Tax effects reclassified to retained earnings	(4)
Accumulated other comprehensive (loss) income, ending balance	$ (17)	$ (18)	$ (35)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2017	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Class of Stock [Line Items]
Proceeds from issuance of equity securities	$ 4,800,000,000	$ 4,800,000,000	$ 0	$ 4,827,000,000	$ 0
Common Stock Issued at Par Value
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	14,025
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,475
Preferred Stock, Depositary Share Ownership Interest, Percentage	5.00%
Preferred Stock, Dividend Rate, Percentage			6.125%
Preferred Stock, Liquidation Preference Per Share			$ 1,000
Depositary Share Liquidation Preference			$ 50
Minimum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			11,700
Maximum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			14,000

Shareholders' Equity - Other Co

Shareholders' Equity - Other Comprehensive Income (Loss), Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income	$ (19)	$ (60)	$ 79

Earnings per Share - Weighted A

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share (Detail) - shares shares in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Average common shares outstanding (shares)	258,354	218,943	212,702
Dilutive share equivalents from share-based plans (shares)	6,267	4,645	4,834
Average common and common equivalent shares outstanding - assuming dilution (shares)	264,621	223,588	217,536

Earnings per Share - Weighted_2

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Footnotes (Detail) - shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0	0
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,000,000	5,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 19, 2013USD ($)	Nov. 09, 2009USD ($)	Apr. 30, 2018USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Loss Contingencies [Line Items]
Rental expense for operating leases					$ 149	$ 110	$ 112
Future minimum rental commitments on noncancelable leases due in 2019					107
Future minimum rental commitments on noncancelable leases due in 2020					94
Future minimum rental commitments on noncancelable leases due in 2021					76
Future minimum rental commitments on noncancelable leases due in 2022					62
Future minimum rental commitments on noncancelable leases due in 2023					48
Future minimum rental commitments on noncancelable leases thereafter					124
Aggregate future purchase commitments					1,046
Loss Contingency Accrual					2,000
QualifiedSettlementFunds					94
Loss Contingency, Receivable					$ 343
RTI Technologies
Loss Contingencies [Line Items]
Damages awarded	$ 113.5	$ 5
Loss Contingency Accrual, Period Increase (Decrease)				$ 337
HerniaProductClaims [Member]
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number					3,154
WomensHealthProductClaims [Member]
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number					1,322
ClaimsLackingSufficientInformation					1,037
NumberOfClaimsInSettlementAgreement					15,021
Damages awarded			$ 68
PaymentstoSupplier					$ 121
FilterProductClaims [Member]
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number					4,515
Compensatory [Member] | WomensHealthProductClaims [Member]
Loss Contingencies [Line Items]
Damages awarded			33
Punitive [Member] | WomensHealthProductClaims [Member]
Loss Contingencies [Line Items]
Damages awarded			$ 35

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Millions	12 Months Ended
	Sep. 30, 2018USD ($)customersegment	Sep. 30, 2017USD ($)customer	Sep. 30, 2016USD ($)customer	Oct. 03, 2016
Segment Reporting Information [Line Items]
Number of principal business segments (segments) | segment	3
Number of customers accounted for 10% or more of revenues (customers) | customer	0	0	0
Asset Impairment Charges			$ 214
Lease Contract Modification Related Charge	$ 0	$ 748	0
Respiratory Solutions
Segment Reporting Information [Line Items]
Disposal Group, Including Discontinued Operation, Revenue			822
Disposal Group, Held-for-sale, Not Discontinued Operations | Respiratory Solutions
Segment Reporting Information [Line Items]
Disposal Group, Including Discontinued Operation, Percent Of Business Sold				50.10%
Medical
Segment Reporting Information [Line Items]
AllocatedCosts		166	175
Asset Impairment Charges	58
Life Sciences
Segment Reporting Information [Line Items]
AllocatedCosts		$ 113	$ 95
Impairment of Intangible Assets (Excluding Goodwill)	81
CR Bard Inc [Member]
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired	478
CR Bard Inc [Member] | Medical
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired	60
CR Bard Inc [Member] | Interventional
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired	$ 418

Segment Data - Financial Inform

Segment Data - Financial Information for Company's Segments (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenues	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 3,166	$ 3,035	$ 2,969	$ 2,922	$ 15,983	$ 12,093	$ 12,483
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									1,173	976	1,074
Acquisitions and other restructurings									744	354	728
Total Assets	53,904				37,734				53,904	37,734	25,586
Total Capital Expenditures									895	727	693
Total Depreciation and Amortization									1,978	1,088	1,114
Operating Segments
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									4,137	2,927	2,845
Total Assets	50,938				22,388				50,938	22,388	23,002
Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									8,616	7,419	7,965
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									2,624	1,907	1,807
Total Assets	23,493				15,552				23,493	15,552	16,370
Total Capital Expenditures									560	486	464
Total Depreciation and Amortization									1,028	773	801
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									4,330	3,988	3,829
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									1,207	772	793
Total Assets	4,225				4,056				4,225	4,056	3,848
Total Capital Expenditures									255	212	200
Total Depreciation and Amortization									275	254	254
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									3,037	685	689
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									306	248	245
Total Assets	23,219				2,780				23,219	2,780	2,784
Total Capital Expenditures									65	16	18
Total Depreciation and Amortization									658	52	56
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisitions and other restructurings									744	354	728
Net interest expense									(641)	(445)	(367)
Corporate and All Other
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest									(1,578)	(1,152)	(676)
Total Assets	$ 2,966				$ 15,347				2,966	15,347	2,584
Total Capital Expenditures									14	13	12
Total Depreciation and Amortization									$ 17	$ 10	$ 3

Segment Data - Revenues to Unaf

Segment Data - Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 3,166	$ 3,035	$ 2,969	$ 2,922	$ 15,983	$ 12,093	$ 12,483
Long-Lived Assets	46,494				19,101				46,494	19,101	19,220
Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	375				366				375	366	329
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									8,768	6,504	6,893
Long-Lived Assets	38,982				13,151				38,982	13,151	14,075
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									3,298	2,588	2,674
Long-Lived Assets	5,640				4,421				5,640	4,421	3,747
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									2,460	1,744	1,692
Long-Lived Assets	851				578				851	578	586
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,457	1,257	1,225
Long-Lived Assets	$ 645				$ 584				$ 645	$ 584	$ 483

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Cost Relating to Share-Based Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 332	$ 177	$ 196
Income tax benefit recognized	79	61	69
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	36	30	29
Selling and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	136	113	106
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	29	24	22
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 130	$ 10	$ 39

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 332	$ 177	$ 196
SARs vesting period	4 years
SARs terms of award	10 years
Stock Issued under SARs exercised (in shares)	1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	166,000
Unrecognized compensation expense for all non-vested share-based awards	$ 307
Weighted-average remaining life non-vested share-based awards	2 years 13 days
Shares were authorized for future grants	7,100,000
Shares issuable under deferred compensation plan	338,000
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferral plan, shares held in trust	135,000
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Performance period	3 years
Weighted average remaining vesting term	9 months 14 days
Performance-Based Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	0.00%
Performance-Based Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	200.00%
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Weighted average remaining vesting term	1 year 17 days
Time-Vested Restricted Stock Units | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	1 year
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 130	$ 10	$ 39
Acquisitions and other restructurings | CR Bard Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 126

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods (Detail) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.32%	2.33%	2.17%
Expected volatility	19.00%	20.00%	19.00%
Expected dividend yield	1.33%	1.71%	1.76%
Expected life	7 years 5 months	7 years 6 months 12 days	7 years 7 months 9 days
Fair value derived (USD per share)	$ 46.10	$ 33.81	$ 27.69

Share-Based Compensation - Summ

Share-Based Compensation - Summary of SARs Outstanding (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
SARs, beginning balance (shares) | shares	6,466
SARs, granted (shares) | shares	4,295
SARs, exercised (shares) | shares	(2,511)
SARs, forfeited, canceled or expired (shares) | shares	(264)
SARs, ending balance (shares) | shares	7,986
SARs, Vested and expected to vest at ending balance (shares) | shares	7,732
SARs, Exercisable at ending balance (shares) | shares	5,450
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
SARs, weighted average exercise price, beginning balance (USD per share) | $ / shares	$ 117.94
SARs, weighted average exercise price, granted (USD per share) | $ / shares	123.97
SARs, weighted average exercise price, exercised (USD per share) | $ / shares	98.67
SARs, weighted average exercise price, forfeited, canceled or expired (USD per share) | $ / shares	163.69
SARs, weighted average exercise price, ending balance (USD per share) | $ / shares	125.73
SARs, weighted average exercise price, vested and expected to vest (USD per share) | $ / shares	124.10
SARs, weighted average exercise price, exercisable (USD per share) | $ / shares	$ 102.66
SARs, weighted average remaining contractual term	5 years 10 months 17 days
SARs, weighted average remaining contractual term, vested and expected to vest	5 years 9 months 22 days
SARs, weighted average remaining contractual term, exercisable	4 years 10 months 24 days
SARs, aggregate intrinsic value | $	$ 1,080
SARs, aggregate intrinsic value, vested and expected to vest | $	1,059
SARs, aggregate intrinsic value, exercisable | $	$ 863

Share-Based Compensation Summar

Share-Based Compensation Summary of SARs Exercised (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Total intrinsic value of SARs exercised	$ 333	$ 148	$ 148
Share Based Compensation Tax Benefit Realized From Exercise Of Stock Appreciation Rights	90	53	52
Total fair value of SARs vested	$ 107	$ 30	$ 24

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding (Detail) - $ / shares shares in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	1,080
Granted, sock units (shares)	338
Distributed, stock units (shares)	(119)
Forfeited, canceled or expired, stock units (shares)	(267)
Stock units, ending balance (shares)	1,032	1,080
Stock units, vested and expected to vest at ending balance (shares)	548
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 161.64
Granted, stock units weighted average grant date fair value (USD per share)	251.75	$ 174.92	$ 153.73
Distributed, stock units exercise price (USD per share)	156.65
Forfeited, canceled or expired, stock units exercise price (USD per share)	173.67
Stock units exercise price, ending balance (USD per share)	190.57	$ 161.64
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 192.35
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	2,136
Granted, sock units (shares)	2,903
Distributed, stock units (shares)	(1,368)
Forfeited, canceled or expired, stock units (shares)	(906)
Stock units, ending balance (shares)	2,765	2,136
Stock units, vested and expected to vest at ending balance (shares)	2,585
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 142.06
Granted, stock units weighted average grant date fair value (USD per share)	216.06	$ 165.96	$ 145.57
Distributed, stock units exercise price (USD per share)	167.86
Forfeited, canceled or expired, stock units exercise price (USD per share)	178.87
Stock units exercise price, ending balance (USD per share)	194.92	$ 142.06
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 193.90

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding Footnote (Detail) shares in Thousands	12 Months Ended
	Sep. 30, 2018shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Percentage of target payout on which performance-based restricted stock units are based	200.00%
Expected forfeited performance-based restricted stock units (shares)	64
Units in excess of the expected performance payout (shares)	420

Share-Based Compensation Weight

Share-Based Compensation Weighted Average Grant Date Fair Value of Restricted Stock Units (Details) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 251.75	$ 174.92	$ 153.73
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 216.06	$ 165.96	$ 145.57

Share-Based Compensation Fair V

Share-Based Compensation Fair Value of Stock Units Vested (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 31	$ 32	$ 22
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 362	$ 139	$ 114

Benefit Plans - Net Pension and

Benefit Plans - Net Pension and Other Postretirement Cost (Detail) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 136	$ 110	$ 81
Interest cost	90	61	72
Expected return on plan assets	(154)	(112)	(109)
Amortization of prior service credit	(13)	(14)	(15)
Amortization of loss	78	92	77
Settlements	2	0	7
Net pension cost	137	138	113
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Net pension cost	$ 34	$ 43	$ 35

Benefit Plans - Additional Info

Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Percent of total assets domestic plans		69.00%
Cost of the savings incentive plan		$ 89	$ 67	$ 61
Fixed Income Funds
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		40.00%
Diversified
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		28.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		32.00%
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 2,642	1,932	1,855
Pension plan projected benefit obligations		3,246	2,647	$ 2,719
Estimated net actuarial loss that will be amortized from accumulated other comprehensive income		(79)
Estimated prior service credit costs that will be amortized from accumulated other comprehensive income		(14)
Employer contribution		400	54
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Estimated prior service credit costs that will be amortized from accumulated other comprehensive income		(5)
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		1,821	1,254
Employer contribution		287
United States | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		536	369
Foreign Plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		821	678
Pension plan projected benefit obligations		$ 1,064	917
Percent of total plan assets foreign plans		31.00%
Foreign Plans | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 314	256
Domestic Plan [Member] | Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plan projected benefit obligations		$ 148	$ 165
Subsequent Event [Member] | United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Employer contribution	$ 200

Benefit Plans - Change in Benef

Benefit Plans - Change in Benefit Obligation, Change in Fair Value of Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Amounts recognized in the Consolidated Balance Sheets at September 30:
Long-term Employee Benefit Obligations	$ (1,056)	$ (1,168)
Pension Plans
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning obligation	2,647	2,719
Service cost	136	110	$ 81
Interest cost	90	61	72
Plan amendments	0	1
Benefits paid	(162)	(123)
Impact of acquisitions (divestitures)	(758)	19
Actuarial gain	(82)	(134)
Settlements	(122)	(1)
Other, includes translation	19	(36)
Ending obligation	3,246	2,647	2,719
Change in fair value of plan assets:
Beginning fair value	1,932	1,855
Actual return on plan assets	70	134
Employer contribution	400	54
Benefits paid	(162)	(123)
Impact of acquisitions (divestitures)	(539)	13
Settlements	(122)	(1)
Other, includes translation	(15)	26
Ending fair value	2,642	1,932	$ 1,855
Funded Status at September 30:
Unfunded benefit obligation	(604)	(715)
Amounts recognized in the Consolidated Balance Sheets at September 30:
Other	15	9
Salaries, wages and related items	(15)	(17)
Long-term Employee Benefit Obligations	(604)	(707)
Net amount recognized	(604)	(715)
Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30:
Prior service credit	60	74
Net actuarial loss	(982)	(1,065)
Net amount recognized	$ (921)	$ (991)

Benefit Plans - Pension Plans w

Benefit Plans - Pension Plans with Accumulated Benefit Obligations (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Retirement Benefits [Abstract]
Accumulated benefit obligation exceeds the fair value of plan assets, projected benefit obligation	$ 2,618	$ 2,551
Accumulated benefit obligation exceeds the fair value of plan assets, accumulated benefit obligation	2,533	2,470
Accumulated benefit obligation exceeds the fair value of plan assets, fair value of plan assets	2,012	1,833
Projected benefit obligation exceeds the fair value of plan assets, projected benefit obligation	3,121	2,613
Projected benefit obligation exceeds the fair value of plan assets, fair value of plan assets	$ 2,502	$ 1,889

Benefit Plans - Weighted Averag

Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Detail) - Pension Plans	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
U.S. Plans
Net Cost
Discount rate	3.71%	3.42%	4.15%
Expected return on plan assets	7.20%	7.25%	7.50%
Rate of compensation increase	4.51%	4.25%	4.25%
Benefit Obligation
Discount rate	4.26%	3.72%	3.42%
Rate of compensation increase	4.29%	4.51%	4.25%
Foreign Plans
Net Cost
Discount rate	2.30%	1.70%	2.84%
Expected return on plan assets	4.95%	4.65%	5.02%
Rate of compensation increase	2.31%	2.33%	2.33%
Benefit Obligation
Discount rate	2.30%	2.25%	1.70%
Rate of compensation increase	2.36%	2.30%	2.33%

Benefit Plans - Expected Benefi

Benefit Plans - Expected Benefit Payments (Detail) $ in Millions	Sep. 30, 2018USD ($)
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
2,019	$ 213
2,020	202
2,021	208
2,022	209
2,023	214
2024-2028	1,096
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
2,019	14
2,020	14
2,021	13
2,022	13
2,023	12
2024-2028	$ 54

Benefit Plans - Fair Value Meas

Benefit Plans - Fair Value Measurements of U.S. Plan Assets (Detail) - Pension Plans - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,642	$ 1,932	$ 1,855
United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,821	1,254
United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	155
United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	484	232
United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	257	107
United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	122	98
United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	536	369
United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	39	40
United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	356	252
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	600	371
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	101	89
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	199	83
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	85	63
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	176	62
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	39	40
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	34
Significant Other Observable Inputs (Level 2) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	497	346
Significant Other Observable Inputs (Level 2) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	155
Significant Other Observable Inputs (Level 2) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	383	144
Significant Other Observable Inputs (Level 2) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57	25
Significant Other Observable Inputs (Level 2) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	22
Significant Other Observable Inputs (Level 2) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	724	537
Net Asset Value [Member] | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	12
Net Asset Value [Member] | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	360	307
Net Asset Value [Member] | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 356	$ 217

Benefit Plans - Fair Value Me_2

Benefit Plans - Fair Value Measurements of Foreign Plan Assets (Detail) - Pension Plans - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,642	$ 1,932	$ 1,855
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	821	678
Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	14
Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6	5
Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	150	127
Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	96	64
Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	314	256
Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	28
Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	26
Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	114	98
Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	74	62
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	546	459
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	0
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	1
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	104	83
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63	57
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	299	242
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	28
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	55	47
Foreign Plans | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	146	108
Foreign Plans | Significant Other Observable Inputs (Level 2) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	13
Foreign Plans | Significant Other Observable Inputs (Level 2) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	3
Foreign Plans | Significant Other Observable Inputs (Level 2) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	45
Foreign Plans | Significant Other Observable Inputs (Level 2) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33	7
Foreign Plans | Significant Other Observable Inputs (Level 2) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	26
Foreign Plans | Significant Other Observable Inputs (Level 2) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	20	15
Foreign Plans | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	114	98
Foreign Plans | Significant Unobservable Inputs (Level 3) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	114	98	$ 102
Foreign Plans | Significant Unobservable Inputs (Level 3) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	13
Net Asset Value [Member] | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	13
Net Asset Value [Member] | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value [Member] | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Benefit Plans - Changes in Fair

Benefit Plans - Changes in Fair Value of Foreign Pension Assets Measured Using Level 3 Inputs (Detail) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning fair value	$ 1,932	$ 1,855
Exchange rate changes	(15)	26
Ending fair value	2,642	1,932
Foreign Plans
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning fair value	678
Ending fair value	821	678
Foreign Plans | Insurance contracts
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning fair value	98
Ending fair value	114	98
Foreign Plans | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning fair value	98
Ending fair value	114	98
Foreign Plans | Significant Unobservable Inputs (Level 3) | Insurance contracts
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning fair value	98	102
Return on assets	2	1
Purchases, sales and settlements, net	15	(11)
Transfers in from other categories	1	1
Exchange rate changes	(2)	4
Ending fair value	$ 114	$ 98

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2017	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Dec. 29, 2017	Apr. 03, 2017
Business Acquisition [Line Items]
Proceeds from issuance of equity securities	$ 4,800,000,000	$ 4,800,000,000	$ 0	$ 4,827,000,000	$ 0
BusinessCombinationConsiderationTransferredEquityInterestsRecognizedAsIncreaseToAdditionalPaidInCapitalCommonStock						$ 6,500,000,000
BusinessCombinationConsiderationTransferredEquityInterestsRecognizedAsDecreaseToTreasuryStock						2,100,000,000
TransitionTaxPayableAcquiree						$ 175,000,000
CR Bard Inc [Member]
Business Acquisition [Line Items]
Cash consideration per share (USD per share)						$ 222.93
Conversion factor						0.5077
Proceeds from Issuance of Debt		$ 9,600,000,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			0
Product liability and other legal reserves						$ 2,029,000,000
Business Combination, Acquisition Related Costs			56,000,000	$ 25,000,000
Business combination, pro forma information, revenue of acquiree since acquisition date,			3,000,000,000
Business combination, pro forma information, loss of acquiree since acquisition date			107,000,000
Recognition Of Fair Value Adjustment To Inventory Acquired			$ 478,000,000
CME [Member]
Business Acquisition [Line Items]
BusinessAcquisitionPercentageOfVotingInterestsPreviouslyAcquired							40.00%
Percentage of interest acquired							60.00%
Developed Technology [Member] | CR Bard Inc [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			14 years
Developed Technology [Member] | Measurement Input, Discount Rate [Member] | CR Bard Inc [Member]
Business Acquisition [Line Items]
Business Combination Intangible Asset Measurement Input			8.00%
Customer relationships | CR Bard Inc [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			13 years
Customer relationships | Measurement Input, Discount Rate [Member] | CR Bard Inc [Member]
Business Acquisition [Line Items]
Business Combination Intangible Asset Measurement Input			8.00%

Acquisitions - Fair Value of Co

Acquisitions - Fair Value of Consideration Transferred (Detail) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Noncash consideration-fair value of shares issued		$ 8,004	$ 0	$ 0
Noncash consideration-fair value of stock options and other equity awards		$ 613	$ 0	$ 0
CR Bard Inc [Member]
Business Acquisition [Line Items]
Cash consideration	$ 16,400
Noncash consideration-fair value of shares issued	8,004
Noncash consideration-fair value of stock options and other equity awards	613
Total consideration transferred	$ 25,017

Acquisitions Acquisition - Fair

Acquisitions Acquisition - Fair Value of Company's Ordinary Shares Issued (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 29, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Fair value of the Company’s issued shares		$ 8,004	$ 0	$ 0
CR Bard Inc [Member]
Business Acquisition [Line Items]
Total Bard shares outstanding	73,359,000
Conversion factor	0.5077
Conversion of Bard shares outstanding	37,243,000
Conversion of pre-acquisition equity awards	104,000
Total number of the Company's share issued	37,347,000
Closing price of the Company’s stock	$ 214.32
Fair value of the Company’s issued shares	$ 8,004

Acquisitions Fair Value of Asse

Acquisitions Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill		$ 23,600	$ 7,563	$ 7,419
CR Bard Inc [Member]
Business Acquisition [Line Items]
Cash and equivalents	$ 1,480
Trade receivables	472
Inventories	974
Property, plant and equipment	553
Developed technology	10,469
Customer relationships	1,146
Other assets	624
Total identifiable assets acquired	15,718
Payables, accrued expenses and other liabilities	1,276
Short term and long-term debt	1,692
Product liability and other legal reserves	2,029
Deferred tax liabilities	1,713
Total liabilities assumed	6,711
Net identifiable assets acquired	9,007
Goodwill	16,009
Net assets acquired	$ 25,017

Acquisitions - Summary of Pro F

Acquisitions - Summary of Pro Forma Results (Detail) - CR Bard Inc [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Revenues	$ 16,947	$ 15,781
Net Income	$ 390	$ 1,145
Diluted Earnings per Share (USD per share)	$ 0.90	$ 3.60

Divestiture - Additional Inform

Divestiture - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Oct. 03, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale			$ 137	$ 0
Proceeds from divestitures, net			534	165	$ 158
Gain on Sale of Investments		$ 303	303	0	0
Advanced Bioprocessing [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue			106	$ 103	95
Respiratory Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue					$ 822
Vyaire Medical [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures, net		$ 435
Disposal Group, Held-for-sale, Not Discontinued Operations | Advanced Bioprocessing [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale			$ 137
Disposal Group, Held-for-sale, Not Discontinued Operations | Respiratory Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Percent Of Business Sold						50.10%
Disposal Group, Including Discontinued Operation, Percent Of Business Retained						49.90%
Subsequent Event [Member] | Advanced Bioprocessing [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures, net	$ 475

Business Restructuring Charge_2

Business Restructuring Charges Business Restructuring Charges - Changes in Restructuring Balance (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
CR Bard Inc [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 0	$ 0	$ 0
Charged to expense	292	0	0
Cash payments	(106)	0	0
Non-cash settlements	(153)	0	0
Other adjustments	0	0	0
Ending balance	33	0	0
CR Bard Inc [Member] | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0
Charged to expense	136	0	0
Cash payments	(103)	0	0
Non-cash settlements	0	0	0
Other adjustments	0	0	0
Ending balance	33	0	0
CR Bard Inc [Member] | Other
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0
Charged to expense	156	0	0
Cash payments	(3)	0	0
Non-cash settlements	(153)	0	0
Other adjustments	0	0	0
Ending balance	0	0	0
CareFusion and Other Initiatives [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	55	69	62
Charged to expense	52	85	526
Cash payments	(79)	(57)	(148)
Non-cash settlements	(1)	(9)	(39)
Other adjustments	0	(33)	(332)
Ending balance	27	55	69
CareFusion and Other Initiatives [Member] | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	49	67	62
Charged to expense	30	27	81
Cash payments	(56)	(45)	(76)
Non-cash settlements	0	0	0
Other adjustments	0	0	0
Ending balance	23	49	67
CareFusion and Other Initiatives [Member] | Other
Restructuring Reserve [Roll Forward]
Beginning balance	6	2	0
Charged to expense	22	58	445
Cash payments	(23)	(12)	(72)
Non-cash settlements	(1)	(9)	(39)
Other adjustments	0	(33)	(332)
Ending balance	$ 4	$ 6	$ 2

Business Restructuring Charge_3

Business Restructuring Charges Business Restructuring Charges - Changes in Restructuring Balance Footnote (Detail) $ in Millions	12 Months Ended
	Sep. 30, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Capitalized Computer Software, Impairments	$ 214
Respiratory Solutions | Disposal Group, Held-for-sale, Not Discontinued Operations
Restructuring Cost and Reserve [Line Items]
Gain (Loss) on Disposition of Business	(81)
IT Restructuring
Restructuring Cost and Reserve [Line Items]
Change in workforce related costs	13
Care Fusion Corporation
Restructuring Cost and Reserve [Line Items]
Change in workforce related costs	$ 40

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,475	$ 7,811
Accumulated Amortization	3,073	1,986
Unamortized intangible assets	39	69
Acquired in-process research and development
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	37	67
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,966	3,508
Accumulated Amortization	1,782	1,029
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,584	3,393
Accumulated Amortization	861	564
Product rights
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	121	131
Accumulated Amortization	58	54
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	407	408
Accumulated Amortization	84	65
Patents and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	397	370
Accumulated Amortization	$ 288	$ 274

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 1,255	$ 533	$ 552
Estimated aggregate amortization expense in 2019	1,472
Estimated aggregate amortization expense in 2020	1,350
Estimated aggregate amortization expense in 2021	1,347
Estimated aggregate amortization expense in 2022	1,338
Estimated aggregate amortization expense in 2023	$ 1,333

Intangible Assets - Reconciliat

Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 7,563	$ 7,419
Acquisitions (c)	15,217	143
Divestiture (b)	(116)	(25)
Goodwill, Transfers	0
Goodwill, Purchase Accounting Adjustments	959	4
Goodwill, Foreign Currency Translation Gain (Loss)	(24)	22
Goodwill, ending balance	23,600	7,563
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	6,802	6,688
Acquisitions (c)	3,923	119
Divestiture (b)	0	(25)
Goodwill, Transfers	(877)
Goodwill, Purchase Accounting Adjustments	228	4
Goodwill, Foreign Currency Translation Gain (Loss)	(22)	16
Goodwill, ending balance	10,054	6,802
Life Sciences
Goodwill [Roll Forward]
Goodwill, beginning balance	761	731
Acquisitions (c)	76	24
Divestiture (b)	(59)	0
Goodwill, Transfers	0
Goodwill, Purchase Accounting Adjustments	(2)	0
Goodwill, Foreign Currency Translation Gain (Loss)	(2)	6
Goodwill, ending balance	775	761
Interventional
Goodwill [Roll Forward]
Goodwill, beginning balance	0	0
Acquisitions (c)	11,218	0
Divestiture (b)	(57)	0
Goodwill, Transfers	877
Goodwill, Purchase Accounting Adjustments	732	0
Goodwill, Foreign Currency Translation Gain (Loss)	0	0
Goodwill, ending balance	$ 12,771	$ 0

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax	$ 81,000,000	$ (159,000,000)
Reclassification of terminated interest rate swaps to interest expense within the next 12 months	6,000,000
Forward exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	3,100,000,000	2,500,000,000
Fixed To Floating
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	1,200,000,000	375,000,000
Commodity forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	0	$ 0
Euro Member Countries, Euro | Debt [Member] | Net Investment Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	2,700,000,000
United Kingdom, Pounds | Debt [Member] | Net Investment Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	$ 324,000,000

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2016	Sep. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 228		$ 2,026
Remaining cash equivalents	913		12,153
Fair value of long-term debt	18,800		19,200
Fair value of debt classified from long term to short term	$ 1,893		$ 206
Asset Impairment Charges		$ 214
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Respiratory Solutions | Disposal Group, Held-for-sale, Not Discontinued Operations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) on Disposition of Business		$ 81
Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Impairment Charges	$ 58
Life Sciences
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 81

Debt - Summary of Short-Term De

Debt - Summary of Short-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017
Short-term Debt [Line Items]
Other Short-term Borrowings	$ 10		$ 3
Short-term debt	$ 2,601		203
2.133% Notes due June 6, 2019
Short-term Debt [Line Items]
Interest rate	2.133%
Current portion of long-term debt	$ 724		0
0.368% Notes due June 6, 2019
Short-term Debt [Line Items]
Interest rate	0.368%	0.368%		0.368%
Current portion of long-term debt	$ 1,157		0
4.900% Notes due April 15, 2018
Short-term Debt [Line Items]
Interest rate	4.90%
Current portion of long-term debt	$ 0		200
Term Loan Facility due September 5, 2019 [Member]
Short-term Debt [Line Items]
Short-term Debt	$ 710		$ 0

Debt - Additional Information (

Debt - Additional Information (Detail) € in Millions, £ in Millions	1 Months Ended			3 Months Ended			12 Months Ended
	Jan. 31, 2018	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2018EUR (€)	Jun. 30, 2018GBP (£)	Mar. 31, 2018EUR (€)	Dec. 29, 2017USD ($)	Jun. 30, 2017EUR (€)	Dec. 31, 2016EUR (€)
Debt Instrument [Line Items]
Short-term debt, weighted average interest rate							1.58%	4.90%
Aggregate annual maturities of long-term debt, 2019							$ 3,300,000,000
Aggregate annual maturities of long-term debt, 2020							2,800,000,000
Aggregate annual maturities of long-term debt, 2021							2,300,000,000
Aggregate annual maturities of long-term debt, 2022							3,800,000,000
Aggregate annual maturities of long-term debt, 2023							1,700,000,000
Letters Of Credit Issuable Under Credit Facility							100,000,000
Line Of Credit Facility Maximum Additional Principal Amount Commitments							500,000,000
Line of Credit Facility, Maximum Borrowing Capacity							2,750,000,000
Debt Instrument, Repurchased Face Amount		$ 1,717,000,000	$ 1,689,000,000	$ 539,000,000	$ 461,000,000	$ 1,717,000,000
Debt Instrument, Repurchase Amount		1,776,000,000	1,764,000,000	559,000,000	465,000,000	$ 1,776,000,000
Long-Term Debt							18,894,000,000	$ 18,667,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax		$ 31,000,000	$ 42,000,000	3,000,000	13,000,000		$ (16,000,000)	(73,000,000)	$ 0
Notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Long-Term Debt					$ 452,000,000
1.000% Notes due December 15, 2022
Debt Instrument [Line Items]
Interest rate			1.00%				1.00%								1.00%
Long-Term Debt							$ 576,000,000	586,000,000
1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Interest rate			1.90%				1.90%								1.90%
Long-Term Debt							$ 575,000,000	585,000,000
0.368% Notes due June 6, 2019
Debt Instrument [Line Items]
Interest rate		0.368%			0.368%	0.368%	0.368%					0.368%		0.368%
Long-Term Debt							$ 0	823,000,000
Debt instrument, face amount					$ 370,000,000							€ 300
Floating Rate Notes due December 29, 2020
Debt Instrument [Line Items]
Long-Term Debt							$ 996,000,000	0
Debt instrument, face amount					$ 1,000,000,000
Notes 4.400% due January 15, 2021 and notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Long-Term Debt				$ 556,000,000
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Interest rate				1.401%			1.401%			1.401%	1.401%
Long-Term Debt							$ 346,000,000	0
Debt instrument, face amount				$ 354,000,000						€ 300
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Interest rate				3.02%			3.02%			3.02%	3.02%
Long-Term Debt							$ 324,000,000	$ 0
Debt instrument, face amount				$ 337,500,000							£ 250
Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument, Term						3 years	364 days
Maximum borrowing capacity of syndicated credit facility		$ 2,250,000,000				$ 2,250,000,000	$ 750,000,000
Proceeds from Long-term Lines of Credit							230,000,000
Borrowings under credit facility							710,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Term						5 years
Maximum borrowing capacity of syndicated credit facility							2,250,000,000
Borrowings under credit facility							0
Syndicated Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity of syndicated credit facility							$ 1,500,000,000
Exchanged Notes [Member] | Notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.00%
CR Bard Inc [Member] | Exchanged Notes [Member]
Debt Instrument [Line Items]
Principal Amount Outstanding After Exchange													$ 111,000,000
Long-Term Debt													1,150,000,000
CR Bard Inc [Member] | Exchanged Notes [Member] | Notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Interest rate				3.00%			3.00%			3.00%	3.00%
Long-Term Debt													500,000,000
CR Bard Inc [Member] | Exchanged Notes [Member] | Notes 4.400% due January 15, 2021 [Member]
Debt Instrument [Line Items]
Interest rate				4.40%			4.40%			4.40%	4.40%
Long-Term Debt													$ 500,000,000
CR Bard Inc [Member] | Issued Notes [Member]
Debt Instrument [Line Items]
Long-Term Debt		9,675,000,000				$ 9,675,000,000
Euro Member Countries, Euro | 1.000% Notes due December 15, 2022
Debt Instrument [Line Items]
Debt instrument, face amount | €															€ 500
Euro Member Countries, Euro | 1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Debt instrument, face amount | €															€ 500
Euro Member Countries, Euro | 0.368% Notes due June 6, 2019
Debt Instrument [Line Items]
Debt instrument, face amount | €														€ 700
Long-term Debt [Member]
Debt Instrument [Line Items]
Long-Term Debt		$ 1,745,000,000	$ 1,727,000,000			$ 1,745,000,000

Debt - Summary of Long-Term Deb

Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-Term Debt	$ 18,894			$ 18,667
2.133% Notes due June 6, 2019
Debt Instrument [Line Items]
Interest rate	2.133%
Long-Term Debt	$ 0			723
0.368% Notes due June 6, 2019
Debt Instrument [Line Items]
Interest rate	0.368%		0.368%		0.368%
Long-Term Debt	$ 0			823
2.675% Notes due December 15, 2019
Debt Instrument [Line Items]
Interest rate	2.675%
Long-Term Debt	$ 1,123			1,121
2.404% Notes due June 5, 2020
Debt Instrument [Line Items]
Interest rate	2.404%
Long-Term Debt	$ 998			996
3.250% Notes due November 12, 2020
Debt Instrument [Line Items]
Interest rate	3.25%
Long-Term Debt	$ 699			698
Floating Rate Notes due December 29, 2020
Debt Instrument [Line Items]
Long-Term Debt	$ 996			0
3.125% Notes due November 8, 2021
Debt Instrument [Line Items]
Interest rate	3.125%
Long-Term Debt	$ 990			1,003
2.894% Notes due June 6, 2022
Debt Instrument [Line Items]
Interest rate	2.894%
Long-Term Debt	$ 1,793			1,791
Floating Rate Notes due June 6, 2022
Debt Instrument [Line Items]
Long-Term Debt	$ 498			497
1.000% Notes due December 15, 2022
Debt Instrument [Line Items]
Interest rate	1.00%					1.00%
Long-Term Debt	$ 576			586
3.300% Notes due March 1, 2023
Debt Instrument [Line Items]
Interest rate	3.30%
Long-Term Debt	$ 296			296
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Interest rate	1.401%	1.401%
Long-Term Debt	$ 346			0
3.875% Notes due May 15, 2024
Debt Instrument [Line Items]
Interest rate	3.875%
Long-Term Debt	$ 182			182
3.363% Notes due June 6, 2024
Debt Instrument [Line Items]
Interest rate	3.363%
Long-Term Debt	$ 1,738			1,736
3.734% Notes due December 15, 2024
Debt Instrument [Line Items]
Interest rate	3.734%
Long-Term Debt	$ 1,368			1,367
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Interest rate	3.02%	3.02%
Long-Term Debt	$ 324			0
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Long-Term Debt	$ 177			0
1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Interest rate	1.90%					1.90%
Long-Term Debt	$ 575			585
3.700% Notes due June 6, 2027
Debt Instrument [Line Items]
Interest rate	3.70%
Long-Term Debt	$ 2,383			2,381
7.000% Debentures due August 1, 2027
Debt Instrument [Line Items]
Interest rate	7.00%
Long-Term Debt	$ 156			166
6.700% Debentures due August 1, 2028
Debt Instrument [Line Items]
Interest rate	6.70%
Long-Term Debt	$ 154			164
6.000% Notes due May 15, 2039
Debt Instrument [Line Items]
Interest rate	6.00%
Long-Term Debt	$ 246			246
5.000% Notes due November 12, 2040
Debt Instrument [Line Items]
Interest rate	5.00%
Long-Term Debt	$ 296			296
4.875% Notes due May 15, 2044
Debt Instrument [Line Items]
Interest rate	4.875%
Long-Term Debt	$ 331			331
4.685% Notes due December 15, 2044
Debt Instrument [Line Items]
Interest rate	4.685%
Long-Term Debt	$ 1,159			1,189
4.669% Notes due June 6, 2047
Debt Instrument [Line Items]
Interest rate	4.669%
Long-Term Debt	$ 1,484			1,484
Other long-term debt
Debt Instrument [Line Items]
Long-Term Debt	$ 8			$ 3

Debt - Debt Exchange (Detail)

Debt - Debt Exchange (Detail) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Long-Term Debt		$ 18,894			$ 18,667
Notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Long-Term Debt				$ 452
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Long-Term Debt		$ 177			$ 0
CR Bard Inc [Member] | Exchanged Notes [Member]
Debt Instrument [Line Items]
Long-Term Debt	$ 1,150
Principal Amount Accepted for Exchange	1,039
CR Bard Inc [Member] | Exchanged Notes [Member] | Notes 4.400% due January 15, 2021 [Member]
Debt Instrument [Line Items]
Interest rate		4.40%	4.40%
Long-Term Debt	500
Principal Amount Accepted for Exchange	432
CR Bard Inc [Member] | Exchanged Notes [Member] | Notes 3.000% due May 15, 2026 [Member]
Debt Instrument [Line Items]
Interest rate		3.00%	3.00%
Long-Term Debt	500
Principal Amount Accepted for Exchange	470
CR Bard Inc [Member] | Exchanged Notes [Member] | 6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate		6.70%
Long-Term Debt	150
Principal Amount Accepted for Exchange	$ 137

Debt - Summary of Interest Cost

Debt - Summary of Interest Costs and Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Debt Disclosure [Abstract]
Charged to operations	$ 706	$ 521	$ 388
Capitalized	42	32	30
Total interest costs	748	553	418
Interest paid, net of amounts capitalized	$ 674	$ 435	$ 392

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes from Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Federal	$ 665	$ (230)	$ 312
State and local, including Puerto Rico	73	(20)	17
Foreign	387	200	286
Total, Current	1,124	(50)	616
Domestic	(201)	(64)	(441)
Foreign	(61)	(10)	(78)
Total, Deferred	(262)	(74)	(519)
Income tax provision	$ 862	$ (124)	$ 97

Income Taxes - Components of In

Income Taxes - Components of Income from Continuing Operations Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Domestic, including Puerto Rico	$ (135)	$ (386)	$ (232)
Foreign	1,308	1,362	1,306
Income Before Income Taxes	$ 1,173	$ 976	$ 1,074

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Dec. 29, 2017
Income Tax [Line Items]
Federal statutory tax rate	24.50%	35.00%	35.00%
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNew	21.00%
Other Tax Expense (Benefit)	$ 640
ExpectedDeferredTaxAssetLiabilityReversalRate	21.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ 182
OtherTaxExpenseBenefitTransitionTax	$ 822
TransitionTaxPayableAcquiree				$ 175
Transition Tax, Annual Percentage Payable	8.00%
TransitionTaxEstimatedToBePayable	$ 1,000
OtherTaxExpenseBenefitRelatedtoHistoricUnremittedForeignEarnings	134
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	632	$ 415	$ 478
Unrecognized tax benefits interest and penalties reflected in current year	20	57	(38)
Tax reductions related to tax holidays	$ 101	$ 144	$ 121
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.38	$ 0.64	$ 0.56
Income taxes paid, net	$ 235	$ 265	$ 218
Deferred Income Taxes and Other
Income Tax [Line Items]
Indemnification liability, non-current	$ 140

Income Taxes - Summary of Gross

Income Taxes - Summary of Gross Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at October 1	$ 349	$ 469	$ 593
Increase due to acquisitions	140	0	0
Increase due to current year tax positions	43	41	81
Increase due to prior year tax positions	43	19	10
Decreases due to prior year tax positions	0	(30)	(3)
Decrease due to settlements with tax authorities	(29)	(145)	(147)
Decrease due to lapse of statute of limitations	(3)	(5)	(65)
Balance at September 30	$ 543	$ 349	$ 469

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Compensation and benefits, assets	$ 458	$ 618
Loss and credit carryforwards, assets	1,290	1,098
Other, assets	707	531
Deferred income taxes, assets, gross	2,455	2,247
Valuation allowance, assets	(1,181)	(1,032)
Deferred income taxes, assets	1,275	1,216
Property and equipment, liabilities	253	244
Deferred Tax Liabilities, Other Finite-Lived Assets	2,948	1,584
Other, liabilities	384	164
Deferred income taxes, liabilities, gross	3,585	1,992
Deferred income taxes, liabilities	$ 3,585	$ 1,992

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate (Detail)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Federal statutory tax rate	24.50%	35.00%	35.00%
New U.S. tax legislation (see discussion above)	54.60%	0.00%	0.00%
State and local income taxes, net of federal tax benefit	0.80%	(2.60%)	1.50%
Effect of foreign and Puerto Rico earnings and foreign tax credits	7.30%	(40.80%)	(23.70%)
Effect of Research Credits and Domestic Production Activities	(2.80%)	(2.70%)	(4.40%)
Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2)	6.70%	7.90%	0.00%
Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent	1.30%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent	3.30%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	(4.80%)	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Change in Accounting Method, Percent	(4.50%)	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent	1.60%	0.00%	0.00%
Other, net	(1.10%)	6.30%	0.70%
Total	73.50%	(12.70%)	9.10%

Sale-Type Leases and Financin_2

Sale-Type Leases and Financing Receivables Sales-Type Leases and Financing Receivables - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Receivables [Abstract]
Lessor, Sales-Type Lease, Contract Term	5 years
Lease Contract Modification Related Charge		$ 0	$ 748	$ 0

Supplemental Financial Inform_3

Supplemental Financial Information - Other Income (Expense), Net (Detail) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Losses on debt extinguishment	$ 31	$ 42	$ 3	$ 13	$ (16)	$ (73)	$ 0
Income (Loss) from Equity Method Investments					8	3	8
Losses on undesignated foreign exchange derivatives, net					(14)	(11)	(3)
Royalty Income, Nonoperating					51	0	0
Gains on previously held investments					0	24	0
Other					0	3	7
Other income (expense), net					318	(57)	11
Vyaire Medical [Member]
Income (Loss) from Equity Method Investments					$ 288	$ (3)	$ 0

Supplemental Financial Inform_4

Supplemental Financial Information - Additional Information (Detail) - CR Bard Inc [Member] $ in Millions	Dec. 29, 2017USD ($)
Condensed Income Statements, Captions [Line Items]
Inventories	$ 974
Property, plant and equipment	$ 553

Supplemental Financial Inform_5

Supplemental Financial Information - Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 58	$ 67	$ 62
Additions charged to costs and expenses	89	68	60
Deductions and other	(61)	(76)	(55)
Ending Balance	86	58	67
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	54	61	53
Additions charged to costs and expenses	31	25	23
Deductions and other	(11)	(32)	(14)
Ending Balance	75	54	61
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	4	6	9
Additions charged to costs and expenses	58	43	37
Deductions and other	(50)	(45)	(40)
Ending Balance	$ 12	$ 4	$ 6

Supplemental Financial Inform_6

Supplemental Financial Information - Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Materials	$ 510	$ 313
Work in process	297	271
Finished products	1,644	1,234
Inventories	$ 2,451	$ 1,818

Supplemental Financial Inform_7

Supplemental Financial Information - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Land	$ 173	$ 146
Buildings	2,724	2,496
Machinery, equipment and fixtures	7,405	6,584
Leasehold improvements	182	163
Property, Plant and Equipment, gross	10,485	9,389
Less accumulated depreciation and amortization	5,111	4,752
Property, Plant and Equipment, Net	$ 5,375	$ 4,638

Supplementary Data (Unaudited_2

Supplementary Data (Unaudited) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 3,166	$ 3,035	$ 2,969	$ 2,922	$ 15,983	$ 12,093	$ 12,483
Gross Profit	2,091	2,017	1,604	1,550	1,554	1,504	1,432	1,452	7,262	5,942
Net Income	$ (135)	$ 594	$ (12)	$ (136)	$ 327	$ (132)	$ 344	$ 562	$ 311	$ 1,100	$ 976
Earnings (loss) per Share: (a)
Basic Earnings per Share (USD per share)	$ (0.64)	$ 2.08	$ (0.19)	$ (0.76)	$ 1.27	$ (0.75)	$ 1.61	$ 2.64	$ 0.62	$ 4.70	$ 4.59
Diluted Earnings per Share (USD per share)	$ (0.64)	$ 2.03	$ (0.19)	$ (0.76)	$ 1.24	$ (0.75)	$ 1.58	$ 2.58	$ 0.60	$ 4.60	$ 4.49